TDE -PH-311 Amendment 7  Oral Treprostinil  
CONFIDENTIAL AND PROPRIETARY, UNITED THERAPEUTICS 
CORPORATION  
All content contained herein is confidential and proprietary information of United 
Therapeutics  Corporation and shall not be disclosed in whole or in part except as permitted by 
a signed contract with United Therapeutics Corporation. © 2018 United Therapeutics 
Corporation  
 Page 1 An Open -Label Extension Study  of UT -15C in Subjects with 
Pulmonary Arterial Hypertension  - A Long -Term Follow -up to 
Protocol TDE -PH-310  
IND Number  71, 537  
EudraCT Number  2012 -000098 -21 
Protocol TDE -PH-311 
CONFIDENTIAL  
UNITED THERAPEUTICS CORPORATION  
Original Protocol Date:  
Amendment 01  
Amendment 02  
Amendment 03  
Amendment 04  
Amendment 05  
Amendment 06  
Amendment 07  03 February 2012  
14 March 2012  
13 June 2012  
05 December 2012  
10 March 2014  
09 January 2015  
29 September 2016  
13 July 2018  
 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 2 LIST OF CONTACTS FOR  STUDY  
Contract Research 
Organization:  
PRA International  
4130 Parklake Avenue  
Suite 400  
Raleigh, NC 27614  
USA  Ileana Guerschman  
Project Director  
Telephone:  +54 1152784612  
Facsimile:  +54 1152784601  
GuerschmanIleana@prahs.com  
Study Sponsor  
United Therapeutics Corp.  
55 TW Alexander Drive  
Research Triangle Park, NC  
27709 USA  Aliou Ousmanou, PharmD, MBA  
Director, Clinical Operations   
Telephone:  +1 919 425 -5796  
Facsimile : + 1 919 485 -8352  
aousmanou@unither.com   
United Therapeutics Europe 
Ltd. 
Unither House, Curfew Bell 
Road  
Chertsey, Surrey KT16 9FG  
United Kingdom  Leigh Peterson , PhD  
Vice President, Product 
Development   
Telephone: +1 919 425 -8165  
Facsimile:  +1 919 485 -8352  
lpeterson @unither.com  Jeff Sigman  
Vice President, Clinical Operations  
Telephone:  +1 919 425 -8173  
Facsimile:  +1 919 485 -8352  
jsigman@unither.com  
Medical Monitor  Rob Grover, FRCA  
Vice President, Medical Development  
Telephone:  +44 (0)1932 573805  
Facsimile:  +44 (0)1932 573806  
Email:  310and311medicalmonitoring@unither.com  
SAE Reporting  UT Global Drug Safety  
Telephone:  
 Worldwide:  +1 484 -533-2849  
 Toll-free:  +1 855 -735-7312 (US / Canada only)  
Facsimile:  
 Americas/Japan : +1 919 313 -1297  
 Europe/ROW: +44 1932 573 888  
Email:  drugsafety@unither.com  
Central Clinical Laboratory  
Covance Central Laboratories  
 
 Indianapolis  
8211 SciCor Drive  
Indianapolis, IN  46214 -2985  
USA   
Telephone:  +1 317 271 -1200  
 +1 888 268 -2653  Singapore  
1, International Business Park  
#05-12A/B The Synergy  
Singapore 609917  
Telephone: + 65 -6560 -8793  
 Genève  
7, rue Moïse -Marcinhes  
1217 Meyrin  
Genève  
Switzerland  
Telephone:  +41 58  822 7000  Shanghai  
1st Floor, No. 6 Building  
151 Li Bing Rd  
Zhangjiang Hi -Tech Park 
Shanghai 201203  
China  
Telephone : +86 21 5137 1111  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 3 INVESTIGATOR’S AGREE MENT  
I have read the attached protocol entitled “ An Open -Label Extension Study of UT -15C in 
Subjects with Pulmonary Arterial Hype rtension  - A Long -Term Follow -up to Protocol 
TDE -PH-310” Amendment 7 dated  13 July 2018  and agree to abide by all provisions set forth 
therein.  
I agree to comply with the International Council for  Harmonisation (ICH) Guideline for Good 
Clinical Practice  (GCP)  and applicable Food and Drug Administration  (FDA) 
regulations/guidelines set forth in 21 Code of Federal Regulations Parts 50, 54, 56, and 312 
and local regulations per country.  
I agree to ensure that the confidential information contained in this document will not be used 
for any purpose other than the evaluation or conduct of the clinical investigation without the 
prior written consent of United Therapeutics Corp.  
I also have read the current Investigator ’s Brochure for UT-15C (treprostinil diethanolamine)  
and acknowledge that review of the informat ion contained in the Investigator ’s Brochure is a 
requirement for Investigators before using UT-15C (treprostinil diethanolamine)  in a clinical 
study . 
   
Signature of Principal Investigator   Date  
   
   
Printed Name of Principal Investigator    
 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 4 LIST OF  ABBREVIATIONS  
6MWD  6-Minute Walk Distance  
6MWT  6-Minute Walk Test  
AE Adverse Event  
ALT  Alanine Aminotransferase  
AST  Aspartate Aminotransferase  
BID Twice daily  
Cmax Maximum Plasma Concentration  
CTD  Connective Tissue Disease  
CVD  Cardiovascular Disease  
CYP  Cytochrome P450  
eCRF  Electronic Case Report Form  
EC Ethics Committee  
ERA  Endothelin Receptor Antagonist  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GGT  Gamma -Glutamyl Transferase  
GLP  Good Laboratory Practice  
HIV Human Immunodeficiency Virus  
H-L Hodges -Lehmann  
ICF Informed Consent Form  
ICH International Council for  Harmonisation  
IND Investigational New Drug  
IRB Institutional/Independent Review Board  
IV Intravenous (ly) 
IVRS  Interactive Voice Response System  
IWRS  Interactive Web Response System  
NTP  National Toxicology Program  
NT-proBNP  N-Terminal Pro -Brain Nat riuretic Peptide  
PAH  Pulmonary Arterial Hypertension  
PDE5 -I Phosphodiesterase -5 Inhibitor  
PGI 2 Prostacyclin  
SAE  Serious Adverse Event  
SC Subcutaneous  
SD Standard Deviation  
sGC Soluble Guanylate Cyclase Stimulator  
TID 3 Times Daily  
UT-15C Treprostinil Diethanolamine  
WHO  World Health Organization  
WOCBP  Woman of Childbearing Potential  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 5 PROTOCOL SYNOPSIS  
Title  Open -Label Extension Study of UT -15C in Subjects with 
Pulmonary Arterial Hypertension  - A Long -Term Follow -up 
to Protocol TDE -PH-310 
Study Phase  III 
Indication  Pulmonary Arterial Hypertension  (PAH)  
Primary Objective   To provide UT-15C for eligible subjects who 
participated in Study Protocol TDE -PH-310 
Secondary Objective(s)   To assess the long -term safety of oral UT -15C 
 To assess the effect of continued long-term therapy 
with UT -15C on exercise capacity  (6-Minute Walk 
Distance [6MWD ]/Borg dyspnea score ), World Health 
Organization ( WHO ) Functional Class, and 
N-terminal pro -brain natriuretic peptide ( NT-proBNP ) 
(at Week 48 only)  
Exploratory Objective   Optional evaluation of pharmacogenomics  
Study Design  Multi -center, open -label study for eligible patients who 
participated in TDE -PH-310 
Sample Size  Up to 850 subjects from Protocol TDE -PH-310 will be 
enrolled.  
Summary of Subject  
Eligibility Criteria  Participation and completion of required visits from 
TDE -PH-310.  Discontinued due to clinical worsening in 
TDE -PH-310.  All ongoing subjects at the time the number of 
adjudicated clinical worsening (morbidity or mortality) events 
specified in Protocol TDE -PH-310 has occurred will be 
eligible to participate in this open -label study.  
Drug Dosage  
and Formulation  All subjects will receive oral treprostinil diethanolamine 
(UT-15C) sustained release tablets.  Study drug will be 
provided in 0.125, 0.25, 0.5, 1.0, and 2.5 mg sustained -release  
(SR)  tablets to be administered 3 times daily  (TID)  
immediately after (~10 minutes) consuming food.  
For subjects who were randomly allocated to UT -15C in 
TDE -PH-310, the initial dose of UT -15C in the open -label 
study will be based upon their final dose in TDE -PH-310.  
Dose escalation of UT -15C may occu r in either 0.125 or 
0.25 mg increments no more than every 24 hours based on 
adverse effects and signs and symptoms of PAH.  
For subjects who were randomly allocated to placebo in 
Protocol TDE -PH-310, dosing of UT -15C will be initiated at 
0.125  mg TID.  Dos e escalations can occur no more than 
every 24 hours ( 3 consecutive doses) in 0.125 mg increments 
TID during the first 4 weeks of the study.  Following 4 weeks 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 6 of treatment, dose escalation may occur no more than every 
24 hours in either 0.125 mg or 0.25 mg  increments TID every 
24 hours.  There is no maximum dose specified for this study.  
Note that sudden dose escalations or reductions may lead to 
intolerable adverse effects or worsening PAH and gradual 
dose titrations are recommended to reduce the risk to s ubjects.  
Control Group  None  
Route of  
Administration  Oral 
Procedures  Study visits will occur at Baseline, Weeks 6, 12 , and every 
12 weeks thereafter.  Study visits will continue until either 
UT-15C becomes commercially available within the 
respective territories , or the study is discontinued by the 
Sponsor .  Study assessments will include:  
 6-Minute Walk Test (6MWT)/Borg dyspnea score  
 WHO Functional Class  
 NT-proBNP (Week 48 only)  
 Safety (vital signs, adverse events  [AEs] , clinical 
laboratory parameters,  concomitant medications)  
 Optional assessment of pharmacogenomics.  
Statistical Considerations  All data will be summarized in tables and listings.  
Sponsor  United Therapeutics Corp.  
55 T. W. Alexander Drive  
Research Triangle Park, NC  27709  
USA  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 7 TABLE OF CONTENTS  
LIST OF CONTACTS FOR  STUDY  ................................ ................................ ....................  2 
INVESTIGATOR’S AGREE MENT  ................................ ................................ .....................  3 
LIST  OF ABBREVIATIONS  ................................ ................................ ................................  4 
PROTOCOL SYNOPSIS  ................................ ................................ ................................ ....... 5 
TABLE OF CONTENTS  ................................ ................................ ................................ ........  7 
Table of In -Text Figures  ................................ ................................ ................................ .........  9 
1 BACKGROUND AND RATIO NALE  ................................ ................................ ..........  10 
1.1 DEFINITION OF CLINICAL PROBLEM  ................................ .............................  10 
1.2 TREPROSTINIL DIETHANOLAMINE BACKGROUND  ................................ .. 11 
1.2.1  General Pharmacology  ................................ ................................ ..........................  11 
1.2.2  General Toxicology  ................................ ................................ ................................  12 
1.2.3  Clinical Pharmacology  ................................ ................................ ..........................  15 
1.2.4  Efficacy and Safety Data  ................................ ................................ .......................  18 
1.3 RATIONALE FOR DEVELOPMENT OF STUDY DRUG IN 
DISEASE/CONDITION  ................................ ................................ ............................  23 
1.4 CLINICAL HYPOTHESIS  ................................ ................................ .......................  24 
2 OBJECTIVES  ................................ ................................ ................................ .................  24 
2.1 PRIMARY OBJECTIVE  ................................ ................................ ..........................  24 
2.2 SECONDARY OBJECTIVES  ................................ ................................ ..................  24 
2.3 EXPLORATORY OBJECTIVE  ................................ ................................ ...............  24 
3 EXPERIMENTAL PLAN  ................................ ................................ ..............................  24 
3.1 STUDY DESIGN  ................................ ................................ ................................ ........  24 
3.2 OVERALL SCHEDULE OF TIMES AND EVENTS  ................................ ............  25 
3.3 CLINICAL ASSESSMENTS  ................................ ................................ ....................  26 
3.3.1  Efficacy  ................................ ................................ ................................ ...................  26 
3.3.1.1  Six-Minute Walk Test  ................................ ................................ ........................  26 
3.3.1.2  Borg Dyspnea Score  ................................ ................................ ...........................  26 
3.3.1.3  WHO Functional Class  ................................ ................................ ......................  26 
3.3.1.4  N-terminal proBNP  ................................ ................................ ............................  26 
3.3.1.5  Optional Pharmacogenomics  ................................ ................................ ............  26 
3.3.2  Safety  ................................ ................................ ................................ ......................  27 
3.3.2.1  Vital Signs  ................................ ................................ ................................ ...........  27 
3.3.2.2  Physical Examination  ................................ ................................ ........................  27 
3.3.2.3  Clinical Laboratory Assessments  ................................ ................................ ..... 27 
3.3.2.4  Adverse Event Assessments  ................................ ................................ ..............  27 
3.3.2.5  Concomitant Medications  ................................ ................................ .................  28 
3.4 NUMBER OF CENTERS  ................................ ................................ ..........................  28 
3.5 NUMBER OF SUBJECTS  ................................ ................................ ........................  28 
3.6 ESTIMATED STUDY DURATION  ................................ ................................ .........  28 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 8 4 SUBJECT ELIGIBILITY  ................................ ................................ ..............................  29 
4.1 INCLUSION CRITERIA  ................................ ................................ ..........................  29 
4.2 EXCLUSION CRITERIA  ................................ ................................ .........................  29 
4.3 PRESCRIBED THERAPY  ................................ ................................ ........................  30 
4.3.1  Concomitant Medications  ................................ ................................ .....................  30 
5 SUBJECT ENROLLMENT  ................................ ................................ ...........................  30 
5.1 TREATMENT ASSIGNMENT  ................................ ................................ ................  30 
5.2 RANDOMIZATION  ................................ ................................ ................................ .. 30 
5.3 BLINDING  ................................ ................................ ................................ ..................  30 
6 DRUGS AND DOSING (OR  TREATMENT PROCEDURE S) ................................ . 30 
6.1 DRUG DOSAGE, ADMINISTRATION AND SCHEDULE  ................................ . 30 
6.2 ACCESS TO BLINDED TREATMENT ASSIGNMENT  ................................ ..... 31 
6.3 COMPLIANCE  ................................ ................................ ................................ ..........  32 
7 EXPERIMENTAL PROCEDU RES  ................................ ................................ .............  32 
7.1 TREATMENT PHASE  ................................ ................................ ..............................  32 
7.1.1  Baseline/Study Entry  ................................ ................................ .............................  32 
7.1.2  Week 6 Visit  ................................ ................................ ................................ ...........  34 
7.1.3  Week 12 Visit  ................................ ................................ ................................ .........  34 
7.1.4  Follow -up Visits (every 12 weeks)  ................................ ................................ ........  35 
7.1.5  Study Termination Visit  ................................ ................................ ........................  35 
8 STUDY TERMINATION  ................................ ................................ ...............................  36 
8.1 CRITERIA FOR SUBJECT WITHDRAWAL  ................................ .......................  36 
8.2 CRITERIA FOR TERMINATING THE STUDY  ................................ ..................  36 
8.3 CRITERIA FOR DISCONTINUING THE SITE  ................................ ...................  37 
9 ADVERSE EVENT REPORT ING  ................................ ................................ ................  37 
9.1 DEFINITIONS  ................................ ................................ ................................ ...........  37 
9.1.1  Adverse Event  ................................ ................................ ................................ ........  37 
9.1.2  Serious Adverse Event  ................................ ................................ ..........................  37 
9.1.3  Adverse events associated with progression of PAH  ................................ ..........  38 
9.2 DOCUMENTATION OF ADVERSE EVENTS  ................................ .....................  38 
9.3 REPORTING RESPONSIBILITIES OF THE INVESTIGATOR  .......................  39 
9.4 PREGNANCY  ................................ ................................ ................................ ............  39 
9.5 SAFETY REPORTS  ................................ ................................ ................................ .. 40 
10 STATISTICAL CONSIDER ATIONS  ................................ ................................ ..........  40 
10.1  DATA PROCESSING  ................................ ................................ ................................  40 
10.2  SAMPLE SIZE  ................................ ................................ ................................ ...........  40 
10.3  ANALYSIS PLAN  ................................ ................................ ................................ ...... 41 
10.4  OTHER ANALYSES  ................................ ................................ ................................ . 41 
11 PACKA GING AND FORMULATION  ................................ ................................ ........  41 
11.1  CONTENTS OF STUDY DRUG  ................................ ................................ ..............  41 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 9 11.2  LABELING  ................................ ................................ ................................ .................  41 
11.3  STORAGE AND HANDLING OF CLINICAL TRIAL MATERIAL  .................  42 
11.4  SUPPLY AND RETURN OF CLINICAL TRIAL MATERIAL  ...........................  42 
11.5  DRUG ACCOUNTABILITY  ................................ ................................ ....................  42 
12 REGULATORY AND ETHIC AL OBLIGATION  ................................ ......................  43 
12.1  ICH GCP OR APPLICABLE REGULATORY REQUIREMENTS  ....................  43 
12.2  INFORMED CONSENT REQUIREMENTS  ................................ .........................  43 
12.3  INDEPENDENT ETHICS COMMITTEE/INSTITUTIONAL REVIEW 
BOARD  ................................ ................................ ................................ .......................  43 
12.4  PRESTUDY DOCUMENTATION REQUIREMENTS  ................................ .........  44 
12.5  SUBJECT CONFIDENTIALITY  ................................ ................................ .............  44 
13 ADMINISTRATIVE AND L EGAL OBLIGATIONS  ................................ .................  44 
13.1  PROTOCOL AMENDMENTS AND STUDY TERMINATION  ..........................  44 
13.2  STUDY DOCUMENTATION AND STORAGE  ................................ ....................  45 
13.3  STUDY MONITORING AND DATA COLLECTION  ................................ ..........  45 
14 REFERENCES  ................................ ................................ ................................ ................  46 
15 APPENDICES  ................................ ................................ ................................ .................  47 
15.1  PROCEDURE FOR SIX MINUTE WALK EXERCISE TEST AND BORG 
DYSPNEA SCORE  ................................ ................................ ................................ .... 47 
15.2  WHO FUNCTIONAL CLASS FOR PAH  ................................ ...............................  49 
15.3  CLINICAL LABORATORY PARAMETERS  ................................ .......................  50 
15.4  GUIDELINES AND DEFINITIONS FOR RECORDING ADVERSE 
EVENTS  ................................ ................................ ................................ ......................  51 
15.5  EXPECTED EVENTS ATTRIBUTABLE TO THE PROGRESSION OF 
PULMONARY ARTERIAL HYPERTENSION (SYSTEM ORGAN CLASS 
AND PREFERRED TERM, VER. 16.0)  ................................ ................................ .. 53 
 
Table of In -Text Figures  
Figure 1  Mean Plasma Treprostinil Concentration vs Time Curve Following the 
First Single 0.5 mg Dose of UT -15C on Day 1 and Following the Last 
Dose of 0.5 mg on Day 8 at Steady State  ................................ ........................  17 
Figure 2  Mean Steady -State Plasma Treprostinil Concentration vs Time Curve 
Following Administration of 0.5 mg TID of UT -15C ................................ .... 18 
 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 10 1 BACKGROUND  AND RATIONALE  
1.1 DEFINITION  OF CLINICAL  PROBLEM  
Pulmonary arterial hypertension (PAH), defined as an elevation in pulmonary arterial pressure 
and pulmonary vascular resistance, is a severe hemodynamic abnormality common to a 
variety of diseases and syndromes.  Elevation in pulmonary arterial pressure causes an 
increase in right ventricular afterload, impairing right ventricular function and ultimately 
leading to heart failure and death.  
The typical etiologies of PAH include idiopathic, heritable or associated with collagen  
vascular/ connective tissue disease  (CTD) , portal hypertension, infection with the human 
immunodeficiency virus (HIV), a history of cocaine inhalation , or exposure to appeti te 
suppressant drugs.  An estimated annual incidence of approximately 2 cases per million has 
been reported for idiopathic PAH (Rich, 1987 , Rubin 1997 ). 
There are 3 major factors thought to contribute to the increased pulmonary vascular resistance 
seen in this disease: vasoconstriction, remodeling of the vessel wall, and thrombosis.  There 
are a number of metabolic pathways which contribute to these changes that involve vasoactive 
mediators such as the vasodilators nitric oxide and prostacyclin, and the vas oconstrictor 
endothelin -1.  These substances affect both vascular tone and remodeling leading to their use 
as pharmacologic targets (Farber, 2004 ). 
Approved pharmacotherapies for PAH include: (1) intravenous prostacyclin (epoprostenol 
sodium or Flolan®, Veletri®); (2) the prostacyclin (PGI 2) analogues, subcutaneous (SC), 
intravenous (IV), and inhaled treprostinil (Remodulin®, Tyvaso®), oral treprostinil 
diethanolamine (Orenitram®), oral selexipag (Uptravi®), and inhaled iloprost (Ventavis®); 
(3) the phosphodiesterase -5 inhibitors (PDE5 -I), tadalafil (Adcirca®) and sildenafil 
(Revatio®); (4)  the oral endothelin receptor antagonists  (ERAs) , bosentan (Tracleer®), 
ambrisentan (Letairis®, Volibris®), and macitentan (Opsumit®), and (5) a soluble guanylate 
cyclase stimulator  (sGC) , riociguat (Adempas®). 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 11 1.2 TREPROSTINIL  DIETHANOLAMINE  BACKGROUND  
1.2.1 General Pharmacology  
Treprostinil, [[(1R,2R,3aS,9aS) 2,3,3a,4,9,9a hexahydro 2 hydroxy 1 [(3S) 3 hydroxyoctyl] 
1H benz [f]inden 5 yl]oxy]  acetic acid, is a chemically sta ble tricyclic analogue of PGI 2. 
The pharmacology of treprostinil has been extensively characterized in well-established  
models all confirming the suitability of the drug for the treatment of PAH following either the 
SC, IV, inhaled (as treprostinil sodium) , or oral (as treprostinil diethanolam ine) routes of 
administration.  
The major pharmacological actions of treprostinil are direct vasodilation of pulmonary and 
systemic arterial vascular beds and inhibition of platelet aggregation.  In vitro , treprostinil 
induced concentration dependent relaxation of rabbit isolated precontracted mesenteric 
arteries, and inhibition of adenosine diphosphate induced platelet aggregation in human and 
rat platelet rich plasma.  In animals, the vasodilatory effects of treprostin il reduce right and 
left ventricular afterload, thereby increasing cardiac output and stroke volume.  Prostacyclins 
lower pulmonary artery pressure, increase cardiac output without affecting the heart rate, 
improve systemic oxygen transport as well as poss ibly reversing pulmonary artery 
remodeling.  There is also increasing evidence that the ability to block the proliferation of 
pulmonary artery smooth muscle cells may contribute, along with vasodilation, to the 
therapeutic effects of prostacyclins in the t reatment of PAH.  The mechanism of action is 
therefore likely to be multifactorial.  
Treprostinil diethanolamine (UT -15C) was selected from a series of treprostinil salts based on 
critical physicochemical characteristics (eg, solubility, hygroscopicity, mel ting point) with a 
goal of delivering treprostinil b y the oral route as a sustained -release (SR) dosage form.  In 
solution, both treprostinil sodium and treprostinil diethanolamine are disassociated from their 
respective salt counter -ions and exist as the freely ionized form of treprostinil.  As a result, the 
bioactive form present in the bloodstream is identical irrespective of the selection of the 
counter -ion.  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 12 A rat blood pressure model study confirmed that the diethanolamine salt of treprostinil 
exhibit s dose dependent pharmacological activity with a cardiovascular profile comparable to 
that of treprostinil.  Overall, no highly active metabolite has been identified, as all the 
metabolites evaluated had greatly reduced activity compared to UT -15C.  Thus, it would 
appear that the observed pharmacological profile of UT -15C reflects the activity of the parent 
molecule, treprostinil, and that the contribution to that profile of any known metabolite that 
would be formed in vivo  would be minimal.  
1.2.2 General  Toxicol ogy 
UT-15C is a novel salt form of Remodulin (treprostinil) Injection and Tyvaso (treprostinil) 
Inhalation Solution, which are approved in the United States and other countries for the 
treatment of patients with PAH.   The active pharmaceutical ingredient, treprostinil, exists as 
the sodium salt in the drug product of Remodulin and Tyvaso.  Given that the only change to 
the drug substance synthesis route for UT -15C is the diethanolamine addition step, and 
treprostinil i s not altered, the bioactive form of treprostinil diethanolamine and treprostinil 
sodium is predicted to be identical.  Therefore, in addition to the nonclinical studies 
conducted with UT -15C, an extensive amount of pharmacology, pharmacokinetic, and 
toxic ology information on treprostinil sodium is available from Remodulin and Tyvaso 
development.  
During the development of Remodulin, treprostinil s odium was administered SC and/ or IV in 
acute toxicity studies, repeat -dose toxicity studies, reproductive toxici ty studies, and 
genotoxici ty studies, and has a well -defined clinical safety profile.  Treprostinil sodium was 
administered via continuous infusion to both rats and dogs in toxicity studies for up to 
6 months, which supported the chronic administration of Remodulin to patients.  
In addition to the extensive toxicology data with treprostinil sodium, the toxicity and 
toxicokinetic profiles of UT -15C have been evaluated in acute and repeat -dose oral toxicity 
studies of up to 13 weeks in duration in rodents and up to 9 months duration in dogs.  UT -15C 
has also been evaluated in reproductive -developmental toxicity studies in pregnant rats and 
rabbits and in an in vivo rat micronucleus assay.  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 13 Nonclinical findings from 13 week toxicology studies with UT -15C have inc luded dose 
dependent, yet transient decreases in mean body weight gain and food consumption in both 
rats and dogs and soft /mucoid stools, diarrhea, and vomitus in dogs.  Many of these findings 
have been seen previously during development of Remodulin and a re consistent with 
prostacyclin induced effects.  In addition, post -mortem findings in rats administered UT -15C 
included changes in organ weight data and histological findings related to the adrenal gland, 
heart, spleen, thymus and bone marrow; some of whi ch were not seen with Remodulin.  The 
majority of these findings were reversible following a 4 -week recovery period.  Data from a 
9-month dog study provides additional toxicology information following chronic dosing.  
UT-15C was reasonably well -tolerated f ollowing daily oral administration at dose levels up to 
35 mg/dog/day for 9 months.  The primary adverse effect was judged to be gastrointestinal 
disturbance, evidenced by increased incidence of soft stools, mucoid stools and diarrhea.  By 
the end of the s tudy, all dogs were in good condition.  No systemic adverse effects were 
detected as judged by ophthalmology, ECG, clinical pathology and histopathological 
examination.  
In vitro  genotoxicity studies with UT -15C have not been conducted; however, data are 
available for such studies using high doses of Remodulin (treprostinil sodium).  Remodulin 
(treprostinil sodium) was non -mutagenic in bacterial reverse mutation assays (Ames assay ) at 
concentrations up to 5,000 mcg/plate with and without S9 metabolic activation, and in the 
mouse lymphoma assay at concentrations up to 400 mcg/mL without S9 metabolic activation 
and up to 300 mcg/mL in the presence of S9.  
UT-15C was tested in vivo  in the rat micronucleus assay, which aimed to evaluate the 
potential of UT -15C to increase the incidence of micronucleated polychromatic erythrocytes 
in bone marrow of rats.  The results of the assay indicated that oral administration of UT -15C 
at total doses  up to and including a dose of 50 mg t reprostinil (equivalent to 63.4  mg 
UT-15C/kg) did not induce a significant increase in the incidence of micronucleated 
polychromatic erythrocytes in either male or female S prague Dawley  rats.  Mortality observed 
at the  high dose indicates systemic exposure of animals to the test article.  Based upon these 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 14 findings, treprostinil diethanolamine (UT -15C) was concluded to be negative in the rat 
micronucleus assay.  
Segment I (rat) and Segment II (rat and rabbit) reproductive  and developmental toxicology 
studies have also been conducted.  No adverse effects for fetal viability /growth and fetal 
development (teratogenicity) were seen in rats at or below 20 mg/kg/day or rabbits at or 
below 0.5  mg/kg/day.  At high doses, there wer e teratogenic effects of UT -15C observed 
when administered to rabbits.  Findings included increased fetal incidence of external, soft 
tissue, and skeletal malformations.  Additionally, a Segment III reproductive and 
developmental toxicology study has been conducted in female rats.  F 0 female rats receiving 
10 mg/kg/day had decreased food consumption and body weights during gestation, increased 
duration of gestation, had slight decreases in the viability and number of pups per litter, and 
pups with decreased  mean neonatal body weights.  F1 pups of females that received 
20 mg/kg/day had abnormalities in physical development (developmental landmarks), reflex 
development, exploratory behavior, learning and memory, and sexual maturation.  
A 6 month carcinogenicity  study in hemizygous Tg.rasH2 mice administered UT -15C at daily 
oral doses of 3, 7.5, 15 mg/kg and 5, 10, 20 mg/kg in females and males, respectively, for 26 -
weeks did not increase the incidence of neoplastic lesions.  A 2 year rat carcinogenicity study 
is ongoing.   Studies have been conducted by the United States National Toxicology Program 
(NTP) to determine whether diethanolamine by itself (without treprostinil or any other drug) 
causes cancer.  Two years of topical administration of diethanolamine to mi ce produced an 
increased incidence (compared to a control group) of malignant liver tumors in males and 
females, as well as an increased incidence of malignant kidney tumors in males.  Doses used 
in this st udy were approximately 720 to 2 900 times higher (based on mg/m2 dosing) than the 
proposed starting doses for the UT -15C clinical studies.  However, in transgenic mice and 
rats, topical administration of diethanolamine for 20 weeks and 2 years, respectively, was not 
associated with the development of any  cancers.  The relevance of the mouse tumor findings 
to humans is currently unknown.  Diethanolamine is listed on the FDA database of inactive 
ingredients for a number of approved drug products with no apparent safety concerns.  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 15 A good laboratory practices (GLP ) cardiovascular s afety pharmacology study 
(Study  1259DU16.003) to evaluate diethanolamine effects, independent of treprostinil, on 
cardiovascular function in telemetered beagle dogs was also  conducted.  Since there are 0.269 
grams of diethanolamine pe r each gram of treprostinil in UT -15C, for this study doses of 
diethanolamine were selected that were similar or higher than the amount of diethanolamine 
contained in the doses of UT -15C assessed in the UT -15C cardiovascular safety 
pharmacology study (Stud y 1259DU16.002).  Doses of 0, 2, 3 and 4 mg/kg/day of 
diethanolamine (equivalent to the amount of diethanolamine administered with 7, 11, and 
15 mg/kg/day of treprostinil, the free acid of UT -15C), were selected to be administered to 
each of 1 group of 4 telemetered male dogs.  Preliminary data support that oral administration 
of diethanolamine at doses up to 2  mg/kg/dose twice daily  (BID)  (4 mg/kg/day) to male dogs 
was not associated with any definitive changes in arterial pressure, heart rate or 
electroca rdiogram parameters.  In addition, no abnormal clinical signs were noted in the 
animals dosed with the vehicle or with any of the doses of diethanolamine.  
1.2.3 Clinical Pharmacology  
In solution, both treprostinil sodium and treprostinil diethanolamine are disas sociated from 
their respective salt counter -ions and exist as the freely ionized form of treprostinil.  As a 
result, the bioactive form present in the bloodstream is identical irrespective of the selection 
of the counter -ion.  Given this premise, the devel opment of this new diethanolamine salt of 
treprostinil is expected to retain the bioactivity and safety profile of treprostinil sodium.  
The most frequent adverse events ( AEs) associated with Remodulin in clinical trials of 
patients with PAH were related to  the pharmacological properties of Remodulin and were 
generally not serious.  These prostacyclin -related AEs included diarrhea, headache, and 
nausea.  Remodulin has not been associated with any significant changes in laboratory 
parameters or end -organ toxi city.  The safety profile noted in the open -label extension study, 
with much longer durations of exposure and a larger, more diverse patient population, was 
consistent with the profile noted in the controlled trials.  To date, over 17,000 subjects and 
patients have been exposed to Remodulin.  This number includes patients who have received 
single administration, to patients receiving continuous infusion for greater than 10 years.  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 16 UT-15C has been administered to approximately 1 800 subjects in Phase 1–3 clinical trials.  
UT-15C doses of up to 3 mg BID have been administered to healthy volunteers and patients 
with PAH have received up to 27.5 mg 3 times daily dosing ( TID) in the ongoing Phase 1–3 
development program.  The average exposure is approximately 2 years; the longest exposure 
is almost 7 years.  
The absolute bioavailability of the UT -15C 1 mg tablet is 17% compared with IV Remodulin.  
Following administration, treprostinil diethanolamine is widely distributed.  Treprostinil is 
approximately 96% protein b ound with no effect on warfarin or digoxin displacement.  
Pharmacokinetic data (area under the curve) indicate that Day 1 pharmacokinetic data are 
predictive of Day 13 , and linearity was observed in plasma exposure comparing 1 mg and 
2 mg doses in healthy volunteers.  Food, particularly a high calorie meal, has been observed to 
increase absorption and prolong the systemic exposure to treprostinil, contributing to the 
desired pharmacokinetic profile.  Consistent with in vitro  studies, cli nical studies assessing 
the impact of induction and inhibition of the cytochrome P450 (CYP) 2C8 and CYP  2C9 
metabolic pathways on treprostinil diethanolamine indicate that CYP 2C8 appears to be of 
major importance and CYP 2C9 of minor importance to in vivo  metabolism of UT -15C in 
humans.  
To date, the majority of UT -15C studies have been conducted with BID dosing.  In an attempt 
to understand the pharmacokinetics of TID a study was conducted in healthy volunteers.  In 
this open -label, single -center study 19 healthy subjects received 0.5 mg TID for 7 days.  On 
the morning of Day 1 subjects received a single 0.5 mg dose, on Day 2 to  Day 7 the subjects 
received TID dosing of 0.5 mg (approximately 8AM, 2PM, and 8PM) with a meal.   On the 
morning of Day 8, the subj ects received a final dose of 0.5 mg.  
Intensive 24 hour pharm acokinetic  sampling occurred following the 8AM doses on Days 1, 7 , 
and 8.   Trough samples were co llected prior to the morning (8 AM) and evening (8PM) doses 
on Days 4, 5 , and 6.  
Nineteen subjects (9 Females :10 Males) with a me an age of 35.2 years (range: 20 to 54 years ) 
were enrolled.  On Day 1 the mean ( ±standard deviation [ SD]) maximum plasma 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 17 concentration ( Cmax) of treprostinil was 0.574 ±0.22 ng/mL, occurring at a m edian time of 
4 hours (range: 2 to 6 hours).  In comparison, the Day 8 mean ( ±SD) Cmax was 0.615 ±0.32 
ng/mL, occurring at a m edian time of 4 hours (range: 1 to 6 hours) (See Figure 1 ). 
Figure 1 Mean Plasma Treprostinil Concentration vs Time Curve Following the 
First Single 0.5 mg Dose of UT -15C on Day 1 and Following the Last Dose 
of 0.5 mg on Day 8 at Steady State  
 
On Day 7, the mean C max (±SD) was 0.810 ±0.491 ng/mL, o ccurring at a median time  of 
14 hours (range: 6 to 20  hours ) following the morning dose  (Figure 2).  This indicates that 
maximum plasma concentration during a daily interval at steady state occurs  after the even ing 
(or third) dose of the day.  

United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 18 Figure 2 Mean Steady -State Plasma Treprostinil Concentration vs Time Curve 
Following Administration of 0.5 mg TID of UT-15C 
 
Mean trough plasma concentrations prior to the morning dose on Days 5, 6 , 7, and 8 were 
0.049, 0.049, 0.050 , and 0.053 ng/mL, respectively.  Mean trough concentrations prior to the 
evening dose on Days 4, 5, 6 , and 7 were 0.487, 0.396, 0.437, and 0.353 ng/mL , respectively.  
Fifteen AEs occurred in 7 subjects and primarily included known prostacyclin class -effect 
related AEs ( eg, headache, diarrhea, and jaw pain).  
A comprehensive description of UT -15C (treprostinil diethanolamine), including the 
pharmacology, toxicology, and clinical studies completed to date may be found in the most 
recent Investigator ’s Brochure.  
1.2.4 Efficacy and Safety Data  
UT-15C has previously been evaluated in 3 randomized, placebo -controlled Phase 3 studies 
(TDE -PH-301, TDE -PH-302, and TDE -PH-308).  Additionally, subjects completing the se 
studies have been provided long -term access to UT -15C in an open -label extension study 
(TDE -PH-304).  To date, over 1,000 PAH patients have been exposed to study drug (UT -15C 
or placebo) in the TDE -PH-301, TDE -PH-302, and TDE -PH-308 studies and over 
800 patients have received UT -15C in the open -label extension study.  

United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 19 TDE -PH-301 was a 16 -week, randomized, double -blind, placebo -controlled, international 
Phase  3 efficacy and safety study of treprostinil diethanolamine (UT -15C), in patients with 
PAH.  Patien ts received UT -15C or placebo BID in combination with an ERA, a PDE5 -I, or 
both.  The primary endpoint was placebo -corrected change in 6MWD fr om Baseline to 
Week  16.  Secondary endpoints included Borg dyspnea sco re, dyspnea -fatigue index, WHO 
Functional C lass, and time to clinical worsening.  Study drug dose was titrated up to a 
maximum of 16 mg BID based on clinical response and study drug tolerability.  
A total of 354 subjects were enrolled with 30% receiving an ERA alone, 25% a PDE5 -I alone, 
and 45% both agents.  The population was 81% female, predominantly WHO Functional 
Class 3 (76%), and had a mean B aseline 6MWD of 346 m.  PAH etiology included idiopathic 
or heritable PAH (66%), or PAH associated with CTD (26%), repaired congenital systemic -
to-pulmonary  shunt (7%), or HIV infection (1%).  There were no remarkable demographic 
differences between treatment groups.  
Twenty -two percent of subjects discontinued UT -15C therapy compared to 14% in the 
placebo group.  The primary reaso n for discontinuation was AEs : 14% in the UT -15C group 
compared to 5% in placebo.  There were 3 deaths in each of the treatment groups.  
The Hodges -Lehmann (H -L) estim ate of 6MWD median change from B aseline at Week  16 
was +11 m (p=0.072).  The change in 6MWD was significant at Week 12 (+13 m, p=0.015).  
The lack of significance at Week 16 may be attributable to the number of subjects who did not 
provide an efficacy measure at Week 16 due to discontinuing from the study prematurely.  
Secondary endpoints of the combined 6MWD and Borg dyspn ea score and the 
dyspnea -fatigue index demonstrated statistically significant changes at Week 16 for UT -15C 
compared to Baseline (p=0.013 and 0.01, respectively).  
TDE -PH-301 was initiated with subjects administered a 1 mg starting dose with dose 
increases in 1 mg increments.  Additional tablet strengths of 0.25 mg and 0.5 mg were made 
available to subjects at sequentially later times in the study.  A post -hoc analysis demonstrated 
that during the course of the study those subjects with access to 0.25 mg tab lets at 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 20 randomization had a lower discontinuation rate due to AEs (0%, n=23) as well as a higher 
H-L estimate of 6MWD treatment effect (+28.5 m) at Week 16.  Presumably titrating up the 
dose of study drug slowly with smaller increments may allow subjects t o tolerate and thereby 
maintain therapy on UT -15C and achieve optimal dosing.  In addition, those subjects that 
were able to titrate to doses between 1.25 and 3.25 mg BID and doses greater than or equal to 
3.5 mg BID also demonstrated a more robust treatme nt effect of +18 and +34 m, respectively.  
Thus, premature discontinuations and inability to achieve doses greater than 1  mg BID during 
TDE -PH-301 appear to have muted the overall treatment effect detected by the study.  
TDE -PH-302 was a 12 -week, randomized  (2:1 UT -15C to placebo), double -blind, 
placebo -controlled, international Phase 3 efficacy and safety study of UT -15C in patients with 
PAH not currently receiving approved background therapy.  The primary endpoint was 
placebo corrected change in 6MWD from Baseline to Week 12.  Secondary endpoints 
included Borg dyspnea score, dyspnea -fatigue index, WHO Functional Class  and time to 
clinical worsening.  Study drug dose was titrated up to a maximum of 12 mg BID based on 
clinical response and study drug tolerabi lity. 
The study enrolled 349 subjects who were not receiving any approved PAH medication, with 
the population for primary analysis consisting of 228 subjects who had access to the 0.25  mg 
tablet strength at randomization.  These subjects were administered UT-15C or placebo  BID, 
with the doses titrated to effect over the course of the 12 -week study.  The majority of 
subjects were in WHO Functional Class  2 (33%) and Class 3 (66%) of varied etiologies, 
including idiopathic or heritable PAH (75%), cardiovascula r disease ( CVD ) associated PAH 
(19%), and PAH associated with HIV or other associated conditions (6%).  The subjects ’ 
mean Baseline 6MWD was approximately 330 m.  
The primary efficacy analysis comparing change in 6MWD from Baseline to Week 12 
between treatm ent groups in the p rimary analysis population (n= 228) was +23 m (p=0.0125, 
H-L estimate).  The UT -15C group improved by a median of +25 m compared to -5 m change 
in the placebo group.  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 21 The combined 6MWD and Borg dyspnea score was also significantly improved  (p=0.0497) at 
Week  12.  Preliminary analysis of other secondary efficacy measures, including change in 
trough 6MWD at Week 11, change in dyspnea fatigue index, change in Borg dyspnea score, 
change in WHO Functional Class , time to clinical worsening (as defined by death, 
transplantation, atrial septostomy, hospitalization due to PAH or at least a 20% decrease in 
6MWD and initiation of another approved PAH therapy), and PAH signs and symptoms at 
Week  12 did not differ significantly between the UT -15C and p lacebo groups (p>0.05).  
An analysis of all 349 subjects enrolled in the study demonstrated that those subjects 
receiving UT -15C improved their median 6MWD by approximately +25.5 m (H -L estimate, 
p=0.0001) as compared to subjects receiving placebo.  
Adverse Events during the study included headache, nausea, diarrhea, and flushing, which 
were expected in subjects receiving prostanoid therapy.  A low discontinuation rate due to 
AEs in the primary analysis population and the type of AEs resulting in discontinuat ion 
(mostly prostacyclin related, which are not life threatening) indicate that use of UT -15C may 
provide a significant improvement in the safety profile of treprostinil and result in a reduction 
in the occurrence of life -threatening AEs compared with pare nteral treprostinil therapy (eg, 
central venous catheter -related blood stream infection).  
TDE -PH-308 was a 16 -week, randomized, double -blind, placebo -controlled, international 
Phase 3 efficacy and safety study of UT -15C in patients with PAH.  Patients rece ived UT -15C 
or placebo BID in combination with either an ERA, a PDE5 -I, or both.  The primary endpoint 
was placebo -corrected change in 6MWD from Baseline to Week  16.  Secondary endpoints 
included Borg dyspnea score, dyspnea -fatigue index, WHO Functional Cl ass and time to 
clinical worsening.  Study drug dose was titrated up to a maximum of 16  mg BID based on 
clinical response and study drug tolerability.  
A total of 310 subjects (157 UT -15C and 153 placebo) were randomized, received a dose of 
study drug, and contributed to the analysis population for the study.  The study population had 
a mean age of 51 years  of age  (range 18 to 76 years), was 78% female and had a diagnosis of 
idiopathic or heritable PAH (65%), PAH related to CVD (31%), PAH related to HIV infe ction 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 22 (2%), or PAH related to repaired systemic -to-pulmonary shunts (1%).  The population was 
predominantly WHO Functional Class  3 (73%) with a mean Baseline 6MWD of 333 m.  As 
for PAH -approved background therapy, 53 (17%) subjects were receiving ERA thera py alone, 
132 (43%) subjects were receiving a PDE5 -I alone, and 125 (40%) subjects were receiving 
the combination of an ERA and a PDE5 -I at Baseline.  The UT -15C and placebo groups were 
well balanced across all Baseline indices.  
The primary efficacy analys is comparing change in 6MWD from Baseline to Week  16 
between treatment grou ps was +10 m (H -L estimate; p= 0.089).  The UT -15C group improved 
by a median of +15 m compared to a +11 m median change in the placebo group.  
Placebo -corrected changes from Baselin e in 6MWD at Week 16 by PAH -approved 
background therapy were as follows: ERA only (H -L estimate of treatment effect = +7.7  m; 
p=0.739), PDE5 -I only (H -L estimate = +15.0 m;  p=0.054), and combination ERA and 
PDE 5-I (H-L estimate = +4.0 m; p= 0.674).  The mea n ± SD maximum dose of UT -15C was 
3.1±1.9 mg BID in the UT -15C group as compared to 6.1± 3.6 mg BID in the placebo group.  
Secondary endpoints including change in 6MWD at Weeks 4, 8, and 12, combined 6MWD 
and Borg dyspnea score, dyspnea -fatigue index, clini cal worsening, serum N-terminal 
proBNP (NT-proBNP ), WHO Functional Class , quality of life, and symptoms of PAH at 
Week 16 were not found to be statistically significant.  
TDE -PH-304 is a long -term, open -label, international, Phase 3 studies designed to prov ide 
access to UT -15C for subjects previously enrolled in studies TDE -PH-301, TDE -PH-302, 
TDE -PH-308, or other specified studies conducted during the UT -15C development program.  
Secondary objectives of the study are to assess the long -term safety of UT -15C in PAH 
patients and to assess the effect of continued therapy on exercise capacity via 6MWD 
following one year of treatment with UT -15C.  As of 01 September 2015 , over 896 subjects 
were enrolled, representing 2377.7  patient -years of exposure.  The mean and ma ximum 
duration of exposure was 138.8  and 444.9 weeks (2.66  and 8.53  years), respective ly.  The 
mean dose of  oral treprostinil  achieved was 3.9, 4.5, 4.8 , 5.0, 5.5, 5.9, and 5.9  mg B ID at 
1 year (N=605), 2  years  (N=472), 3  years (N=337) , 4 years (N= 230), 5 years (N= 119), 6 years 
(N=77), and 7 years (N=37) , respective ly.  Adverse Events were typical of prostacyclin 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 23 therapy; laboratory findings were unremarkable and did not suggest any specific safety 
concerns related to long -term treatment with UT -15C.  Following  12 months of oral 
treprostinil treatmen t, the me an 6M WD inc reased by +25 meters as compared with Baseline.   
Kaplan -Meier analysis of  subject survival demonstrated 1-, 2-, and 3 -year survival estimates 
of appro ximate ly 93.6%, 87.9%, and 82. 2%, resp ective ly. 
1.3 RATIONALE FOR DEVELO PMENT OF STUDY DRUG IN 
DISEASE/ CONDITION  
Prostacyclin is a potent endogenous vasodilator and inhibitor of platelet aggregation.  A 
synthetic salt of prostacyclin (ie , Flolan) has been previously shown to prolong surviva l in 
patients with PAH (Barst 1996 ).  However, due to its very short half -life and chemical 
instability, Flolan has to be continuously infused by IV delivery.  Treprostinil sodium is a 
chemically stable, longer acting analogue that has shown clinical effec tiveness when 
administered by SC, IV (Remodulin , Remodulin Package Insert 201 4], or inhaled routes 
(Tyvaso , Tyvaso Package Insert 2017). 
Parenteral prostacyclins are considered by many providers as the “gold standard” for 
treatment of PAH ; however, they are typically used later in the course of the disease due to 
the risks and difficulties associated with administration.  Consequently, physicians managing 
patients with PAH commonly initiate  treatment with an approved oral mono therapy  to all ow 
patients to benefit from the simplicity of an oral dosage form.  
An innovative salt form, treprostinil diethanolamine, has been developed to deliver 
prostacyclin therapy via the oral route in a solid dosage form.  Because the bioactive species 
is the sam e, treprostinil diethanolamine is expected to retain a similar safety and efficacy 
profile as parenteral treprostinil sodium in the convenience of an oral dosage form.  It has 
been suggested that combination therapy, particularly with a prostacyclin, may p revent or 
delay the progression of the disease and thereby prolong the time to clinical worsening.  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 24 1.4 CLINICAL  HYPOTHESIS  
This open -label study will evaluate the  safety of continued therapy with UT -15C in subjects 
who have completed  TDE -PH-310.  This study wi ll provide long -term, open -label  data 
regarding the safety and efficacy of UT -15C for the treatment of PAH.  
The hypothesis for the frequency of dosing change from BID to TID is that delivering more 
sustained concentrations of treprostinil may allow for sys temic exposure to drug that more 
closely resembles the approved parenteral product, Remodulin, and reduces the occurrence of 
prostacyclin AEs previously seen with the BID regimen.  Both of these improvements may 
allow study subjects to titrate to a more ef fective UT -15C dose and thus study drug may show 
a clinically and statistically significant difference compared to placebo in delaying time to 
first clinical worsening and improving exercise capacity at Week 24.  
2 OBJECTIVES  
2.1 PRIMARY  OBJECTIVE  
The primary obj ective of this study is to provide  UT-15C SR tablets for eligible subjects who 
participated in TDE -PH-310. 
2.2 SECONDARY OBJECTIVES  
Secondary  objectives of this study are : 
 To assess the long -term safety of UT -15C 
 To assess the effect of continued  long-term therapy with UT -15C on exercise capacity 
(6MWD /Borg dyspnea score) , WHO Functional Class , and plasma concentrations of 
NT-proBNP (Week  48 only)  
2.3 EXPLORATORY  OBJECTIVE  
Optional evaluation of pharmacogenomics  
3 EXPERIMENTAL PLAN  
3.1 STUDY DESIGN  
This is an open -label study.  Subject visits will occur at Baseline, Weeks 6 and  12, and every 
12 weeks thereafter.   The study will continue until either oral UT -15C beco mes available 
within the respective  territories or th e study is discontinued by the Sponsor . 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 25 3.2 OVERALL  SCH EDULE OF TIMES AND E VENTS  
Study Timeline  Baselineb 
(Study Entry)  Week 6c Week 12c Follow -up Visits  
(every 12 weeks)c Study 
Termination  
Visitk 
Informed consent  X     
Inclusion /exclusion 
criteria  X     
Vital signs  a X X X X X 
Physical examination  X    X 
6MWT  / 
Borg dyspnea scored X X X X X 
WHO Functional Class  X X X X X 
Clinical laboratory 
assessments  X  X Xe X 
Urine pregnancy test  f X X X X X 
Dose titration  X X X X  
NT-proBNP  X   Xg  
Drug accountability/  
Compliance  X X X X X 
AEs Xh X X X Xi 
Concomitant 
medications  X X X X X 
Phone calls  j X X X X X 
Pharmacogenomic 
Sample (Optional)     Xl Xl 
Abbreviations: 6MWT, 6 -Minute Walk Test; AE, adverse event; NT -proBNP, N -Terminal pro -brain natriuretic 
peptide; WHO, World Health Organization  
a  Vital signs should be conducted following at least 5 minutes of rest and prior to or at least 30 minutes following the  
corresponding 6MWT . 
b  Baseline/study entry assessments  (6MWT/ Borg dyspnea score, WHO Functional Class , clinical laboratory 
parameters, NT -proB NP, vitals, and physical examination) for this study are those collected at the Study 
Termination Visit from Study TDE -PH-310 and prior to initiation of open -label study drug.  Informed consent and 
inclusion/exclusion criteria are exclusive to this Protoco l. 
c  Visit windows are ±14 days . 
d  6MWT must be conducted 3  to6 hours after the last dose of UT -15C.  Subject should rest for 5 minutes prior to 
each 6MWT . 
e  During the follow -up visits, clinical laboratory samples should be collected at the first Follo w-up Visit and every 
other Follow -up Visit thereafter . 
f  If applicable, for women of child -bearing potential (WOCBP) . 
g  NT-proBNP should only be collected at the Follow -up Visit # 3 (Week 48) . 
h Any AEs that are ongoing at the Study Termination Visit fro m Study TDE -PH-310 should be recorded as 
continuing AEs in this open -label study . 
i Any AEs that are ongoing at the Study Termination Visit from Study TDE -PH-311 should be followed for up to 
30 days after completion of the Study Termination Visit . 
j  Phone  calls to the subject should occur at least weekly for the first 12 weeks, and at least monthly thereafter  
k After the Study Termination Visit is completed, subjects should down titrate the study drug over an appropriate 
period of time in accordance with t heir clinical condition.  Once the study drug has been discontinued, any 
remaining supplies should be returned to the clinic for drug accountability . 
l  For subjects consenting to the optional pharmacogenomic sample.  The sample should be collected at the next 
scheduled Follow -up Visit when clinical labs are also collected.  If the subject discontinues prior to the next 
Follow -up Visit, pharmacogenomic sa mples should be collected at the Study Termination Visit.  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 26 3.3 CLINICAL ASSESSMENTS  
3.3.1 Efficacy  
3.3.1.1  Six-Minute Walk Test  
A 6MWT (described in Appendix 15.1) will be conducted at  Baseline as part of Study 
Termination assessments from Protocol TDE -PH-310, Week  6 and Week 12, every 12  weeks 
thereafter , and at the Study Termination Visit .  Before ea ch 6MWT, the subject should rest 
(seated) for at least 5 minutes.   The 6MWTs will be conducted by qualified, trained personnel 
in a designated 6MWT area which meets the requirements outlined in Section  15.1.  The 
6MWT should be conducted approximately 3 to 6 hours after the last dose of UT -15C.  
3.3.1.2  Borg Dyspnea Score  
The Borg dyspnea score will be assessed following each 6MWT.  The Borg dyspnea score is a 
10-point scale rating the maximum level of dyspnea experienced during the 6MWT 
(Appendix 15.1).  Scores range from 0 (for the best condition) to 10 (for the worst cond ition).  
3.3.1.3  WHO Functional Class  
The WHO Functional Class  for PAH (Appendix 15.2) will be assessed at Baseline  as part of 
Study Termination assessments from Protocol TD E-PH-310, Week 6 , Week  12, every 
12 weeks thereafter, and at the Study Termination Visit.  
3.3.1.4  N-terminal pro BNP  
Plasma NT -proBNP  concentration is a useful biomarker for PAH as it is associated with 
changes in right heart morphology and function (Fijalkowska 2006 ).  The NT-proBNP  sample 
collection will occur at Baseline  as part of Study Termination assessm ents from Protocol 
TDE -PH-310 and at Follow -up Visit #3 (Week  48) only.  
3.3.1.5  Optional  Pharmacogenomic s 
For subjects consenting to pharmacogenomic analysis, blood samples will be collected  at the 
first possible Follow -up Visit when clinical labs are also collected.  If the subject discontinues 
prior to the ir next Follow --up Visit, pharmacogenomic samples will be collected at the Study 
Termination Visit .  Pharmacogen omic  samples will be shipped to the central laboratory for 
processing and storage prior to analysis.  Genetic variants will be analyzed to evaluate their 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 27 association with observed clinical response during the blinded Study TDE -PH-310 and 
tolerability to pr ostacyclin therapy.  Subjects who do not wish to participate in the optional 
pharmacogenomic research may still participate in the clinica l study.  
3.3.2 Safety  
3.3.2.1  Vital Signs  
Vital signs will be assessed at Baseline as part of Study Termination assessments from 
Protocol TDE -PH-310 and at all subsequent protocol -required visits.  All vital signs will be 
collected prior to or at least 30 minutes following the corresponding 6MWT.  Vital signs 
include blood pressure, peripheral (radial/brachial artery) heart rate, res piration rate, and 
weight.  Vital signs must be collected following at least 5 minutes of rest to ensure accurate 
measurement.  
3.3.2.2  Physical Examinatio n 
A physical examination will be assessed at Baseline as part of Study Termination assessments 
from Protocol T DE-PH-310 and a t the Study Termination Visit.  
3.3.2.3  Clinical Laboratory  Assessments  
Clinical laboratory parameters will be assessed at  Baseline /Study Entry  as part of Study 
Termination assessments from Protocol TDE -PH-310.  Clinical laboratory assessments will 
also be assessed at  Week 12 , at every other  Follow -up Visit s thereafter , and at the Study 
Termination Visit .  Clinical l aborator y parameters  to be assessed at the study visits are listed 
in Appendix  15.4.  A urine pregnancy test will be collected at every visit for women of 
childbearing potential ( WOCBP ). 
3.3.2.4  Adverse Event Assess ments  
Any AEs that a re ongoing at the Study Termination Visit from Study TDE -PH-310 should be 
recorded as continuing AEs in this open -label study.  Section 9 and Appendix 15.4 provide 
the guidelines and definitions for recording AEs.  
All AEs will be captured  from the time the informed consent form ( ICF) is signed .  All AEs 
should be followed until resolution  (or return to normal or Baseline values) , until the y are 
judged by the  Investigator to no longer be clinically significant, or for up to 30 days if the AE 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 28 extends beyond the final visit.  All serious adverse events ( SAEs ) should be followed until 
resolution, death, or the subject is lost to follow -up even if they are ongoing more than 
30 days after completion of the final visit .  Sections  9 and Appendix  15.4 provide the 
guidelines and definitions for recording AEs.  
Symptoms of PAH (disease -related events) should  only be recorded as an AE if the event is 
either serious, new, or unusual with respect to intensity, frequency, duration as compared to 
symptoms in the subject’s medical history , or there is a reasonable possibility that the event 
was caused by the study drug.  
3.3.2.5  Concomitant Medications  
Concomitant medication may be adjusted as deemed clinically necessary by the Investigator 
during the study.  However, additional prostanoid therapies should not be permanently added.   
Concomitant medications used during the study  will be reviewed at each protocol -required 
visit and recorded as they are prescribed in the Electronic Case Report Form ( eCRF ).  
Concomitant medications that were ongoing at the end of the TDE -PH-310 Study will be 
recorded in the eCRF for the open -label study.  
3.4 NUMBER OF CENTERS  
The centers who partic ipate in S tudy TDE -PH-310 (approximately 1 50) will take part in the 
study.  
3.5 NUMBER OF SUBJECTS  
Up to 850  subjects from TDE -PH-310 may  be eligible to participate in the study.  
3.6 ESTIMATED STUDY DURA TION  
The study will continue for approximately 6 years .  The study may be discontinued at any 
time if, in the opinion of the Investigator s and/or Sponsor , continuation of the study represents 
a serious medical risk to the subjects.   This may include, but is no t limited to, the presence of 
serious, life -threatening, or fatal AEs , or AEs that are unacceptable  in nature severity, or 
frequency .  The Sponsor  reserves the right to discontinue the study for any reason at any time.  
Subjects that discontinue the study will be contacted approximately 30 days ( ±5 days) after 
study drug discontinuation to confirm their survival status .  Subjects may also continue to be 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 29 contacted after the fi nal study visit to assess AEs/ SAEs (see Section 9.2 for additional 
details).  
4 SUBJECT  ELIGIBILITY  
4.1 INCLUSION  CRITERIA  
A subject is eligible to participate in this study if all of the following criteria apply:  
1. The subject voluntarily provides informe d consent to participate in the study.   
2. The subject  participated in Study TDE -PH-310 and  met the definition of clinical 
worsening (as specified in Protocol TDE -PH-310), remained on study drug,  was 
compliant with study procedures and assessments during the  TDE -PH-310 Study or 
was currently enrolled in that study at the time the study was discontinued  by the 
Sponsor . 
3. All WOCBP  must practice true abstinence from intercourse when it is in line with 
their preferred and usual lifestyle, or use 2 different forms of highly effective 
contraception for the duration of the study, and for at least 30 days after discontinuing 
study medication.  Medically acceptable forms of ef fective contraception include: (1) 
approved hormonal contraceptives (such as birth control pill s), (2) barrier methods 
(such as a condom or diaphragm) used with a spermicide, (3) an intr auterine device , or 
(4) partner vasectomy.  For women of childbearing potential, a negative urine 
pregnancy test is required at Baseline (study entry) prior to initi ating study medication.  
WOCBP includes any female who has experienced menarche and who has not 
undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or 
bilateral oophorec tomy) or is not postmenopausal ( define d as amenorrhea for at least 
12 consecutive months ).   
4. Males participating in the study must use a condom during the length of the study, and 
for at least 48 hours after their last dose of study medication.  
4.2 EXCLUSION CRITERIA  
A subject is not eligible to participate in th is study if any of the following criteria apply:  
1. The subject is pregnant or lactating.  
2. The subject has receiv ed infused or inhaled prosta cyclin  therapy  for 29 days or more . 
3. The subjec t was prematurely discontinued from Study TDE -PH-310 for reasons other 
than a clinical worsening  event . 
4. The subject developed a concurrent illness or condition during the conduct of 
TDE -PH-310 which, in the opinion of the Investigator,  would represent a risk to  
overall health if they enrolled in t his study.  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 30 4.3 PRESCRIBED THERAPY  
4.3.1 Concomitant Medications  
In this open -label study, there are no restrictions on concomitant medication s, including the 
approved PAH therapies,  with the exception of the permanent addition (29 days or more) of 
prosta cyclin  or prostacyclin analogue therapy .  Subjects who receive permanent prosta cyclin 
or prostacyclin analogue therapy must discontinue this open -label study.  
5 SUBJECT ENROLLMENT  
5.1 TREATMENT ASSIGNMENT  
All subjects will receive UT -15C SR tablets during this open -label study.  Subjects will retain 
the same subject number as assigned for the TDE -PH-310 study.  
5.2 RANDOMIZATION  
This study is not randomized.  
5.3 BLINDING  
This study is not blinded.  
6 DRUGS AND  DOSING (OR TREATMEN T PROCEDURES)  
6.1 DRUG DOSAG E, ADMINISTRATION AN D SCHEDULE  
The UT -15C tablets are sustained release osmotic tablets .  UT-15C tablets are provided as 
0.125, 0.25, 0.5, 1.0, and 2.5 mg tablet strengths.   The 0.125, 0.25, 0.5, 1 .0, and 2.5 mg tablets 
are colored blue, green, white, yell ow, and pink, respectively.  The formulation contains 
pharmaceutically acceptable excipients used in other approved drug products.  
For subjects who were randomly allocated to receive placebo in TDE -PH-310, dosing of 
UT-15C will be initiated and optimized a s in the previous protocol, including all safety 
monitoring and periodic telephone contacts.  That is, the first dose of UT -15C (0.125 mg) 
should be taken by the subject at the site immediately after (approximately 10 minutes) 
consuming food .  Oral dosing of study drug will be continued at 0.125 mg TID (every 6 to 8 
hours) immediately after ( approximately 10 minutes) consuming food.  Subjects must be 
instructed to take the appropriate amount of UT -15C tablets based upon their prescribed dose.  
For the first 4 weeks, each dose of study drug should be adjusted in 0.125 mg increments no 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 31 more than every 24 hours as clinically indicated.  Following 4 weeks of treatment, each dose 
of study drug may be adjusted in 0.125 or 0.25 mg increments every 24 ho urs as clinically 
indicated.   Doses of UT -15C should continue to be increased in the absence of dose -limiting 
drug-related adverse e ffects , to ensure the subject receives the optimal clinical dose 
throughout the study.   There is no maximum dose  of UT -15C in this open -label study.  
Subjects who were randomly allocated to  receive  UT-15C in TDE -PH-310 will begin the 
open-label study  at the same dose they were receiving at the Study Termination Visit in 
TDE -PH-310, and subsequent adjustments will be made based o n symptoms of PAH and 
adverse effects . 
All s ubjects must be instructed to take the appropriate amount of 0.125, 0.25, 0.5, 1 .0 and/or 
2.5 mg tablets  based upon their prescribed dose.  All d ose changes should be conducted under 
appropriate medical supervision in consultation with the study site.  At least w eekly telephone 
calls between site personnel and the subject should be made during the first 12  weeks of the 
study to monitor AEs  and make  decisions about dose titration.   After Week 12, at least 
monthly  telephone calls should be made to continue to monitor AEs and make decisions 
regarding appropriate dose titrations.   If dose titration is considered appropriate, site personnel 
will instruct  the subject to modify their dose and the dose change will be recorded in source 
documentation.  If it becomes necessary for a subject to modify their dose of UT -15C (eg, due 
to an AE) without prior instructions from site personnel, the subject should be i nstructed to 
contact the site as soon as possible and report any dose changes to site personnel for updating 
in source documentation.  
In the event of continued intolerable AEs, dose reductions may occur.  The exact dose 
reduction and frequency of dose redu ction should be based on the clinical condition of the 
subject and the severity/seriousness of the event.  In general, dose reductions may occur in 
0.125 or 0.25 mg increments every 12 to 24 hours.   Larger dose reductions may be necessary 
in the event of a n emergency situation.  
6.2 ACCESS  TO BLINDED TREATMEN T ASSIGNMENT  
This study is not blinded.  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 32 6.3 COMPLIANCE  
The Principal Investigator or other site personnel under the direction of the Principal 
Investigator will be responsible for dose titration of  UT-15C and re cording all dosing 
information in source documents.  During telephone calls, site person nel will record the 
current dosing regimen  of UT -15C and determine if the subject is taking UT -15C as 
prescribed.  
At scheduled study visits, subjects should be instruct ed to bring all study drug (including 
empty and unused bottles) to the investigational site.  Upon return of study drug at each 
required protocol visits (eg , Weeks 6, 12, 24, etc ), the study coordinator or pharmacist must 
document the number of returned tablets of each strength and determine if the appropriate 
amount of study drug remains based upon the dose of study drug prescribed.  Each subject 
will also be asked at each visit wh ether he or she has been compliant with dosing instructions.  
Subject compliance with the prescribed dosage regimen will be monitored throughout the 
study.  If it is determined that a subject is not compliant with study drug , then site personnel 
must re -educate the subject on proper dosing compliance and  its importance.  Continued 
noncompliance may lead to withdrawal of the subject from the study, after consultation 
between the  Investigator and the Sponsor.  
Upon return of study drug at all protocol -required  on-site study visits (eg , Weeks 6, 12, 24, 
etc), all bottles of study drug will be collected.  Study drug returned will not be re -dispensed 
to the subject.  Site personnel will dispense a new supply of study drug at each protocol -
required visit  for the su bsequent interval.  If necessary, additional study drug may be 
dispensed in between protocol -required visits  at unscheduled visits . 
7 EXPERIMENTAL PROCEDU RES  
7.1 TREATMENT  PHASE  
7.1.1 Baseline /Study Entry  
All data collected at the subject’s Study Termination V isit during TDE -PH-310 and prior to 
initiating open -label study drug will serve as Baseline /Study Entry assessments for this study.  
Following completion of the Study Termination assessments for a subject and entry of 
required data into the interactive voice or  web response system ( IVRS/IWRS ), the site 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 33 personnel will be unblinded to that subject’s treatment assignment.  Subjects must sign an ICF 
and meet inclusion /exclusion criteria specific to this protocol.  The recommended sequence of 
events for Baseline /Study Entry is displayed below : 
 Informed consent  (prior to any study assessments)  
 Inclusion /exclusion criteria  
 Vital signs  (following at least 5 minutes of rest) * 
 Physical examination*  
 WHO Functional Class * 
 AE assessment * 
 6MWT /Borg dyspnea score ( for subjects randomized to UT -15C in TDE -PH-310, the 
6MWT to be initiated 3 to 6 hours after the last dose of UT -15C; 6MWT to be 
conducted following at least 5 minutes of rest; Borg dyspnea score to be conducted 
immediately following 6MWT )* 
 Urine pregnancy test (for  WOCBP )* 
 Clinical laboratory assessments*  
 Plasma NT -proBNP*  
 Study drug dosing ( for subjects randomized to placebo in TDE -PH-310, the initial 
dose of UT -15C in TDE -PH-311 should be taken at the  study  site) 
 Drug accountability  
 Concomitant medications*  
 Weekly te lephone calls  are highly recommended  especially after any dose changes  
*assessments conducted during the Study Termination Visit for  the TDE -PH-310 study  
will not need to be repeated  
The AEs that were ongoing at the end of the TDE -PH-310 study will be recorded as ongoing 
events for this open -label study.   Concomitant medications that were ongoing at the 
TDE -PH-310 Study Termination Visit will be recorded in the eCRF for the open -label study.  
Once the subject signs the ICF for this study, all ongoing AEs must  be recorded and 
documented on the eCRF .  All AEs and concomitant me dications will be reported 
continuously for the duration of the study.  Phone calls to the subject must begin within 
1 week of the subject receiving the first dose of study drug and  continue to be made weekly 
for the first 12 weeks of the study.  After the first 12 weeks, phone calls must be made at least 
monthly.  Dose titration should occur as needed in accordance with  Section 6.1. 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 34 7.1.2 Week 6 Visit  
Subjects are to return to the study site at Week 6.  This vi sit should be conducted within 
14 days of the scheduled visit (as determined by the Baseline /Study Entry Visit) and the 
following assessments  are to occur  in the  order recommended below : 
 Vital signs  (following at least 5 minutes of rest)  
 WHO Functional Class  
 AE assessment  
 6MWT /Borg dyspnea score  (6MWT to be i nitiated 3 to 6 hours after the last dose of 
UT-15C; Borg dyspnea score to be conducted  immediately following 6MWT ) 
 Urine pregnancy test (for WOCBP)  
 UT-15C d ose titration  
 Drug accountability /compliance  
 Concomitant medications  
 Weekly telephone calls  are highly recommended, especially after any dose changes  
7.1.3 Week 12 Visit  
Subjects are to return  to the study site at Week 12.  This vi sit should be conducted within 
14 days of the scheduled visit (as determined by the Baseline /Study Entry Visit) and the 
following assessments are to occur  in the order recommended below : 
 Vital signs  (following at least 5 minutes of rest)  
 WHO Functional Class  
 AE assessment  
 6MWT /Borg dyspnea score (6MWT to be i nitiated 3 to 6 hours after the last dose of 
UT-15C; Borg dyspnea score to be conducted immediately following 6MWT ) 
 Urine pregnancy test (for WO CBP)  
 Clinical laboratory assessments  
 UT-15C dose titration  
 Drug accountability /compliance  
 Concomitant medications  
 Monthly telephone calls  are highly recommended  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 35 7.1.4 Follow -up Visits  (every 12 weeks)  
Subjects should return to the study site every 12 weeks after  the Week 12 visit.  These visits 
should be conducted within 14 days of the scheduled visit (as determined by the 
Baseline /Study Entry Visit).  Assessment of AEs, concomitant medications, and dose titration 
should occur continuously between and during stud y visits.   The recommended sequence of 
events for Follow -up Visits is displayed below:  
 Vital signs  (following at least 5 minutes of rest)  
 WHO Functional Class  
 AE assessment  
 6MWT /Borg dyspnea score (6MWT to be  initiated 3 to 6 hours after the last dose of 
UT-15C; Borg dyspnea score to be conducted immediately following 6MWT ) 
 Urine pregnancy test (for WOCBP)  
 Clinical laboratory assessments*  
 Plasma NT -proBNP* * 
 UT-15C dose titration  
 Drug accountability /compliance  
 Concomitant medications  
 Monthly telephone calls  are highly recommended  
 Collection of blood sample for evaluation of pharmacogenomics (optional) ***  
*to be assessed at the first Follow -up Visit and every other visit thereafter  
**to be assessed at the third Follow -up Visit only (Week 48)  
*** The sample s hould be collected at the next scheduled  Follow -up Visit  when clinical 
labs are also collected .  Subjects must sign an informed consent  prior to sample 
collection.  
7.1.5 Study Termination  Visit  
When subjects discontinue the study, they will complete a Study Term ination Visit. If 
possible, each subject should  remain on study drug until they have completed the Study 
Termination visit. After the Study Termination Visit is completed, subjects should down 
titrate the study drug over an appropriate period of time in ac cordance with their clinical 
condition. Once the study drug has been discontinued, any remaining study drug  should be 
returned to the clinic for drug accountability. The following assessments will take place at the 
Study Termination visit:  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 36  Vital signs  (following at least 5 minutes of rest)  
 Physical examination  
 WHO Functional Class  
 AE assessment  (for AEs ongoing at the Study Termination Visit, assessments to 
continue  for up to 30 days beyond the Study Termination Visit ) 
 6MWT /Borg dyspnea score (if possible, the 6MWT is to be initiated 3 to 6 hours after  
the last dose of UT -15C; Borg dyspnea score to be conducted immediately following 
6MWT ) 
 Urine pregnancy test (for WOCBP)  
 Clinical laboratory assessments  
 Drug accountability /compliance  
 Concomitant medications  
 Collection of blood sample for evaluation of pharmacogenomics (optional) *  
* If a subject discontinues prior to their next Follow -up Visit, pharmacogenomic samples 
will be collected at the Study Termination Visit.    
8 STUDY TERMINATION  
8.1 CRITERIA FOR SUBJECT  WITHDRAWAL  
A subject may voluntarily withdraw or will be withdrawn from the study and/or study drug by 
the Investigator at any time for reasons including, but not limited to, the following:  
 The subject wishes to withdraw from further participation  
 A serious  or life -threatening AE occurs , or the Investigator considers that it is 
necessary to discontinue study drug to protect the safety of the subject  
 The subject deviated from the protocol  
 The subject’s behavior is likely to undermine the validity of his/her r esults  
 The subject becomes pregnant  
When a subject is discontinued from the study, the Investigator will complete the Study 
Termination record and provide an explanation, if needed.  If UT -15C has been administered, 
the Investigator should make every effor t to perform all Study Termination evaluations 
following termination of UT -15C treatment but prior to discharge from the study . 
8.2 CRITERIA  FOR TERMINATING THE  STUDY  
The study may be stopped at any time if, in the opinion of the Investigator and/or Sponsor , 
continuation of the study represents a serious medical risk to the subjects.  This may include, 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 37 but is not limited to, the presence of serious, life -threatening, or fatal AEs , or AEs that are 
unacceptable in nature, severity, or frequency.  The Sponsor  reserves the right to discontinue 
the study for any reason at any time.  
8.3 CRITERIA FOR DISCONT INUING THE SITE  
The study may also be terminated at a given center if:  
 The Principal Investigator elects to discontinue the study  
 The Sponsor  elects to discontinue the study at the site  
 International Council for Harmonisation ( ICH) Good Clinical Practice ( GCP ) or 
applicable regulations are not observed  
 The protocol is repeatedly violated or critical violations are documented  
 Changes in personnel or facilities adversely affect performance of the study  
9 ADVERSE EVENT REPORT ING  
9.1 DEFINITIONS  
9.1.1 Adverse Event  
An AE is any untoward medical experience occurring to a subject during a clinical study  
whether or not it is related to the study drug.  An AE may include an intercurrent illness, 
injury, or any other concomitant impairment of the subject’s health, as well as abnormal 
laboratory findings if deemed to have clinical significance.  AEs may also include worsening 
of an existing symptom or condition or pre /post-treatment events that occur as a result of 
protocol -mandated procedures.  
9.1.2 Serious Adverse Event  
An SAE is an AE occurring at any dose that results in any of the following outcomes:  
 Death  
 A life -threatening AE  
 Inpatient hospitalization or prolongation of existing hospitaliz ation  
 A persistent or significant disability /incapacity  
 A congenital anomaly /birth defect  
In addition, important medical events that may not result in death, be life  threatening, or 
require hospitalization may be considered serious when, based upon appropr iate medical 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 38 judgment, they may jeopardize the subject and require medical /surgical intervention to 
prevent one of the outcomes listed above.  Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in hospitalization, or the development of drug 
dependency or drug abuse.  
Life threatening means that the subject was, in the view of the Investigator, at immediate risk 
of death from the event as it occurred.  It does not mean that the event, had it occurred in a 
more severe form, might have caused death.  
9.1.3 Adverse events associated with progression of PAH  
Expected AEs that may be  related to the progression of a subject’s PAH are defined in 
Append ix 15.5.  All events that occur during the course of the study that are included on this 
list and felt to be related to the progression of the disease by the Investigator should not be 
recorded as AEs in the eCRF as these PAH symptoms will be evaluated and recorded  as an 
efficacy endpoint and /or will be captured as disease -related events.  
However, each event  must be recorded as an AE/SAE in the eCRF, if it meets 1 or more of 
the following criteria:  
 There is a reasonable possibility that it may have been caused by st udy drug . 
 It is serious . 
 It has occurred at greater than expected severity (intensity, frequency, or duration) . 
9.2 DOCUMENTATION OF ADV ERSE EVENTS  
All AEs will be captured  from the time the ICF is signed .  Any AEs that are ongoing at the 
Study Termination Vis it from Study TDE -PH-310 should be recorded as continuing AEs in 
this open -label study.  An AE or SAE occurring during the study  must be documented in the 
subject’s source documents and on the appropriate eCRF page.  Information relating to the 
AE such as onset and cessation date and times, intensity, seriousness, relationship to study 
drug, and outcome is also to be documented in the eCRF (see  Appendix  15.4 for definitions).  
Where possible, AEs should be recorded using standard medical terminology.  If several signs 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 39 or symptoms are clearly related to a medically defined diagnosis or syndrome, the diagnosis 
or syndrome should be recorded on the eCRF page, not the individual signs and symptoms.  
All AEs should be followed until either resolution (or return to normal or baseline values), 
until they are judged by the Investigator to no longer be clinically significant, or for up to 
30 days, if the AE extends beyond the final visit.  All SAEs that occur during the study will be 
followed until resolution, death, or the subject is lost to follow -up even if they are ongoing 
more than 30 days after completion of the final visit.  Supplemental meas urements and/or 
evaluations may be necessary to investigate fully the nature and/or causality of an AE or SAE.  
This may include additional laboratory tests, diagnostic procedures, or consultation with other 
healthcare professionals.  The eCRF pages should  be updated with any new or additional 
information as appropriate . 
9.3 REPORTING RESPONSIBILITIES  OF THE INVESTIGATOR  
All SAEs, regardless of expectedness or causality, must be reported to the Sponsor  within 
24 hours of awareness by fax (+ 1 919 -313-1297  [U.S. /Japan] or + 44 1932 573 888 
[Europe/ ROW])  or email (drugsafety@unither.com).  A  completed SAE report form along 
with any relevant hospital records and autopsy re ports should be provided to Global Drug 
Safety at United Therapeutics Corp.  A  follow -up SAE r eport form must be forwarded to 
Global Drug Safety at United Therapeutics Corp . within 48 hours of the receipt of any 
new/updated information.  The Investigator must also promptly notify their Investigational 
Review Board (IRB) or Ethics Committee (EC) of the SAE, including any follow -up 
information, in accordance with applicable national regulations and guidelines set forth by the 
IRB or EC.  
9.4 PREGNANCY  
If a study subject becomes pregnant during participation in this clinical study, site staff must 
notify the Sponsor  within 24 hours of learning of the pregnancy by completing the Pregnancy 
Notification  Form and either faxing  or emailing this form to Global  Drug Safety at  United 
Therapeutics Corp . (+ 1 919 -313-1297  [U.S./ Japan]  or + 44 1932 573 888 [Europe/ ROW])  or 
drugsafety@unither.com).  Subjects who become pregnant during the study  will be withdrawn 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 40 from active participation in the study  and will discontinue study drug after an appropriate 
period of down -titration.   
United Therapeutics Global Drug Safety Department will follow up with the Investigator to 
ensure appropriate data are provided regarding the outcome of the pregnancy, and to request 
that the Investigator complete a  Pregnancy Outcome Report Form.  Pregnancy only becomes 
an AE /SAE if there is an abnormal outcome, a spontaneous abortion, a termination for 
medical reasons other than PAH, or a congenital anomaly in the offspring.  
9.5 SAFETY REPORTS  
In accordance with national regulations, the Sponsor  or designee, will notify the regulatory 
agencies, Investigators, IRBs , and/or ECs of all relevant AEs (usually those that are 
considered to be possibly attributable to study drug and are bot h serious and unexpected) in 
accordance with the applicable national regulations.  The Investigator must report these SAEs 
to their IRB or EC in accordance with applicable national regulations and guidelines set forth 
by the IRB or EC.  
10 STATISTICAL CONSIDER ATIONS  
10.1 DATA PROCESSING  
Subject data will first be documented in the subject’s source documents, and then transferred 
into the eCRF.  Site personnel will be responsible for recording all subject ’s data into the 
eCRF.  Data for any subject who signs an infor med consent form will be captured in the 
eCRF.  The eCRF screens are to be reviewed by the Principal Investigator for completeness 
and accuracy.  The Principal Investigator must sign each subject’s eCRF to signify their 
approval of the data.  The database will be final when final query resolution has been 
completed and all data management quality control procedures are complete.  
10.2 SAMPLE SIZE  
No formal sample size calculation has been conducted.   All eligible subjects from 
TDE -PH-310 may enter this study.  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 41 10.3 ANALYSIS  PLAN  
All safety and efficacy data will be summarized in tables and listings and analyzed for trends 
over time.  No formal hypothesis testing is planned . 
The safety population will be defined as all subjects in the study that received UT -15C at any  
time during the course of the study.  Safety analyses will be performed on the safety 
population.  All AEs as recorded by the Investigators  will be assigned MedDRA preferred 
terms by the Sponsor  for reporting purposes.  
10.4 OTHER ANALYSES  
Pharmacogenomic sampl es will be evaluated for genetic variants.  Other e xploratory analyses 
may be conducted based on available study data.  
11 PACKAGING AND FORMUL ATION  
11.1 CONTENTS OF STUDY DR UG  
United Therapeutics Corp . will supply  UT-15C for administration during the study.  UT -15C 
tablets  will be  provided as 0.125, 0.25, 0.5, 1, and 2.5  mg strengths for the study.  The UT -
15C tablets are sustained release osmotic tablets. Active treatment will be UT -15C tablets 
provided as 0.125, 0.25, 0.5, 1, and 2.5 mg strengths for the study.  Each tablet contains either 
0.125 mg  treprostinil (equivalent to 0.15875  mg treprostinil diethanolamine), 0.25 mg 
treprostinil (equivalent to 0.3175 mg treprostinil diethanolamine), 0.5 mg treprostinil 
(equivalent to 0.635 mg treprostinil diethanolamine),  1 mg of t reprostinil (equivalent to 
1.27 mg treprostinil diethanolamine), 2.5  mg of treprostinil (equivalent to 3.17 mg treprostinil 
diethanolamine) .  The 0.125, 0.25, 0.5, 1, and 2.5 mg tablets are colored blue, green, white, 
yellow, and pink, respective ly.  UT -15C tablets will be provided in child resistant bottles each 
containing 100 tablets , or in other appropriate packaging configurations as may be required . 
11.2 LABELING   
Each bottle will be labeled in accordance with applicable national regulations, to i nclude at 
least the following information: study drug, study  reference code, strength, quantity, route of 
administration, manufacture or expiry date, lot number, Sponsor  name, address and telephone 
number, and storage conditions .  The labels on the bottles may include blank fields for sites to 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 42 document the following information specific to each bottle, including but not limited to, 
Investigator name, subject number / initials, and date dispensed.  
11.3 STORAGE AND HANDLING  OF C LINICAL TRIAL MATERIAL  
All study drug will be stored at room temperature  (up to 25°C with brief excursions to 30°C 
permitted) .  Study drug should not be frozen , refrigerated, or exposed to heat.  Site personnel 
should refer to investigational medicinal product labeling or regulatory submissions for 
specific requirements by country or region in accordance with local regulations or guidance.  
Study drug at the investigational site will be stored in a securely locked cabinet or enclosure 
with appropriate temperature  monitoring.  Access should be strictly limited to the 
Investigators and their designees.  Neither the Investigators nor any designees may provide 
study drug to any person not participating in this study.  
The pharmacist or appropriate personnel at the inve stigational site  will deliver and retrieve 
each bottle assigned to the subject at each study visit during the course of the study.  Subjects 
should be instructed to return all study drug, including empty bottles, to the appropriate study 
personnel at every  protocol -required visit.  
11.4 SUPPLY AND RETURN OF  CLINICAL TRIAL MATERIAL  
Study sites will be supplied with a sufficient quantity of UT -15C to begin enrollment in the 
study.  An IVRS /IWRS will be utilized to manage resupply with respect to each subject’s visi t 
schedule.  If required, additional study drug may be dispensed to a subject between protocol -
required visits.  At each protocol required visit, all study drug dispensed to the subject should 
be returned to the study site (including empty and unopened bot tles).  A new supply of study 
drug will be dispensed at each protocol -required visit.  
11.5 DRUG ACCOUNTABILITY  
The Investigator is responsible for study drug accountability and reconciliation overall and on 
a per subject basis.  Drug accountability records will  be maintained during the study and these 
records will include:  the amount of study drug received from the Sponsor , the amount 
dispensed to each subject, and the amount of unused drug.  At each visit, site personnel should 
assess drug dispensed, drug retur ned, and dosing information to confirm drug accountability 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 43 and compliance.  Once a representative from the Sponsor  is able to confirm drug 
accountability for that subject, study drug will be returned to a Sponsor  designated location 
for destruction .  Study  drug will not be destroyed on -site by the study staff or in the 
pharmacy.  
12 REGULATORY AND ETHIC AL OBLIGATION  
12.1 ICH GCP  OR APPLICABLE REGUL ATORY REQUIREMENTS  
The study will be conducted in accordance with ICH GCP guidelines and all applicable 
national regulat ions.  The Sponsor  will obtain the required approval from each national 
regulatory authority to conduct the study.  During the conduct of the study, an annual 
development safety update report will be compiled by the Sponsor  for submission to those 
regulato ry authorities and IRBs /ECs that require it.  Any additional national reporting 
requirements as specified by the applicable regulations,  regulatory authorities, or IRB/ EC will 
also be fulfilled during the conduct of the stud y. 
12.2 INFORMED CONSENT REQ UIREMENTS  
Before a subject is enrolled in the study, the Investigator or his/her authorized designees must 
explain the purpose and nature of the study, including potential benefits and risks and all 
study procedures to the subject.  The subject must sign and date a n IRB/EC -approved ICF 
prior to the conduct of any study -related activities.  A copy of the signed ICF will be given to 
the subject and the original will be retained in the study site’s records.  
12.3 INDEPENDENT ETHICS C OMMITTEE/INSTITUTION AL REVIEW BOARD  
Prior to study initiation at each site, the Investigator will obtain approval for the study from an 
appropriate IRB/ EC and provide the Sponsor  with a copy of the approval letter.  The IRB/ EC 
must also review and approve the study site’s informed consent form and  any other written 
information provided to the subject prior to enrollment, as well as any advertising materials 
used for subject recruitment.  Copies of the ICF and advertising materials must be forwarded 
to the Sponsor  for review  before submission to the  IRB/ EC prior to the start of the study.  
If, during the study, it is necessary to amend either the protocol or the ICF, the Investigator is 
responsible for obtaining IRB /EC approval of these amended documents prior to 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 44 implementation.  Copies of the IRB /EC correspondence and approval letters must be sent to 
the Sponsor . 
During the conduct of the study, an annual progress report will be compiled by the Sponsor  
for submission to those IRBs/ECs that require it.  
A written summary of the study will be provided by  the Investigator to the IRB/EC following 
study completion or termination according to the IRB or EC standard procedures.  Additional 
updates will also be provided in accordance with the IRB/EC’s standard procedures.  
12.4 PRESTUDY DOCUMENTATI ON REQUIREMENTS  
Before the com mencement of the clinical study , the following documents (at minimum)  will 
be provided to the site: Investigator ’s Brochure, Protocol, ICF, Budget Agreement, and access 
to an eCRF.  
The site will be required to provide the following documents  (at minimum)  to United 
Therapeutics Corp . or designee prior to study start: Signature page of the protocol, Form FDA 
1572, IRB/EC Composition and Roster, IRB/EC protocol and informed consent approval 
letters, Curriculum Vitae of study staff listed on the Form  FDA 1572 , and authorized clinical 
study  agreement (as required).  
12.5 SUBJECT CONFIDENTIAL ITY 
Every effort will be made to keep medical information confidential.  United Therapeutics 
Corp ., regulatory bodies, and the IRB /EC governing this study may inspect the medical 
records of any subject involved in this study.  The Investigator may release the subject’s 
medical records to employees or agents of the Sponsor , the IRB/ EC or appropriate local 
regulatory agencies for purpos es of checking the accuracy of the data.  A unique number will 
be assigned to all subjects and any report published will not identify the subject s by name . 
13 ADMINISTRATIVE AND L EGAL OBLIGATIONS  
13.1 PROTOCOL AMENDMENTS AND STUDY TERMINATIO N 
Protocol amendments that could potentially adversely affect the safety of participating 
subjects or that alter the scope of the investigation, the scientific quality of the study, the 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 45 experimental design, dosages, duration of therapy, assessment variables,  the number of 
subjects treated, or subject selection criteria may be made only after consultation between 
United Therapeutics Corp . or its designee and the Investigator.  
All protocol amendments must be submitted to and approved by the appropriate regulato ry 
authorities and IRB /EC prior to implementation.  
A report documenting study termination must also be submitted to and acknowledged by the 
appropriate IRB /EC for each study site.  
At the end of the study, where applicable, a final report will be provided t o the local 
regulatory agencies.  
13.2 STUDY DOCUMENTATION AND STORAGE  
In accordance with federal/ national regulations, ICH GCP guidelines, the Investigator must 
retain study records for at least 2 years after the last approval of a marketing application in an 
ICH region and until there are no pending or contemplated marketing applications in an ICH 
region or at least 2 years have elapsed since the formal discontinuation of clinical 
development of the investigational product.  For Investigators in the European Ec onomic 
Area, the study records should be maintained for at least 15 years after study discontinuation.   
The Investigator must notify United Therapeutics Corp . before any disposal or change in 
location of study records.  
13.3 STUDY  MONITORING AND DATA  COLLECTION  
In accordance with federal/ national regulations, ICH GCP guidelines, monitors for United 
Therapeutics Corp . or its designee will periodically contact the site and conduct on -site visits.  
During these visits, the monitor will at a minimum:  confirm ethical  treatment of subjects, 
assess study progress, review data collected, conduct source document verification, verify 
drug accountability periodically, and identify an y issues requiring resolution.  
The Investigator must agree to allow the monitor direct acces s to all relevant documents and 
to allocate his/her time and his/her staff to the monitor to discuss any findings or any relevant 
issues.  In addition, auditors for United Therapeutics Corp . or its designee may periodically 
contact the site and conduct on -site visits . 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 46 14 REFERENCES  
ATS Statement:  Guidelines for the Six-Minute Walk Test.  Am J R espir Crit Care Med .  
2002;166: 111-117. 
Barst RJ, Rubin LJ, Long WA, et al.  A comparison of continuous intravenous epoprostenol 
with conventional therapy for primary pulmonary hypertension.  The Primary Pulmonary 
Hypertension Study Group.  N Engl J Med .  1996;334:296 –302. 
Barst RJ, Gibbs SR, Ghofrani HA, et al.  Updated Evidence -Based Treatment Algorithm in 
Pulmonary Arterial Hypertension.  J of Amer College of Cardiol ogy.  2009;54(1)S78 –S84. 
Farber H W & Loscalzo J.  Mechanisms of Disease: Pulmonary Arterial Hypertension.  
N Engl J Med.  2004;3511(16):1655 –1665.  
Fijalkowska A, Kurzyna M, Torbicki A, et al.  Serum N -Terminal Brain Natriuretic Peptide as 
a Prognostic Para meter in Patients With Pulmonary Hyper tension.  Chest .  2006;129:1313 –
1321.  
Remodulin® (treprostinil) Injection, for subcutaneous or intravenous use [p ackage insert ].  
Research Triangle Park, NC: United Therapeutics Corporation, 2014. 
Rich S,  Dantzker DR, Ayres SM,  et al.  Primary Pulmonary Hypertension : A National 
Prospective Study.  Ann Intern Med .  1987 ;107:216 –223. 
Rubin LJ.  Primary Pulmonary Hypertension.  N Engl J Med.  1997;336:111 –117. 
Tyvaso® (treprostinil) inhalation solution, for oral inhalation  only [ package insert ].  Research 
Triangle Park, NC: United Therapeutics Corporation, 2017. 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 47 15 APPENDICES  
15.1 PROCEDURE FOR SIX MI NUTE WALK EXERCISE T EST AND BORG 
DYSPNEA  SCORE  
General Procedures  
The 6-Minute Walk exercise test should be administered by the same tester and on the same 
course at each study site throughout the study for a given subject.  The administration of 
the test and specifications of the testing area should be generally consistent with the 
American  Thoracic Society guidelines and the usual pra ctice of the investigative site 
[ATS  guidelines; 2002].  
The area used for the 6-Minute Walk Test should be pre -measured at approximately 30 meters 
in length (but no shorter than 15 m eters  [16 yards or 50 feet] in length at minimum) and at 
least 2  to 3 m eters in width.  There should  be no turns or curves to the 6-Minute Walk area.  
The length should be marked with gradations at least every 3 m eters  to ensure the accurate 
measurement of the distance walked.  The area should be well ventilated.  The tester may  be 
at the starting end of the corridor or at the midpoint of the corridor with a stop -watch.  
Intermittent rest periods are allowed if the subject can no longer continue.  If the subject needs 
to rest briefly, he/she may stand or sit and then begin again when he/she is sufficiently rested 
but the clock will continue to run.  At the end of 6 minutes, the tester will call “stop” while 
simultaneously stopping the watch and then measure the distance walked.  The Borg dyspnea 
rating will be administered immedia tely following completion of the 6MWT.  
Instructions to the Subject  
Subjects will be instructed that the preceding meal should be light .  Subjects should be told to 
wear comfortable clothing and sneakers or comfortable walking shoes.  The person 
administer ing the test will use the following exact dialogue with the subject:  
“The purpose of this test is to find out how far you can walk in 6 minutes.  You will start 
from this point and follow the hallway to the marker (eg , chair) at the end, turn around and 
walk back.  When you arrive back at the starting point you will go back and forth again.  
You will go back and forth as many times as you can in the 6 -minute period.  You may 
stop and rest if you need to.  Just remain where you are until you can go on again.   
However, the most important thing about the test is that you cover as much ground as you 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 48 possibly can during the 6 minutes.  I will tell you the time, and I will let you know when 
the 6 minutes are up.  When I say STOP, please stand right where you are.”  
After these instructions are given to the subject, the person administering the test will then 
ask: 
“Do you have any questions about the test?”  
“Please explain to me what you are going to do.”  
The person administering the test will then start the test by saying the following to the subject:  
“Are you ready?”  
“Start when I say ‘ GO.’” 
The person administering the test will tell the subject the time at 2 and 4 minutes by saying:  
“You have completed 2 minutes.”  
And then by saying:  
“You have completed 4 minutes. ” 
No other instruction or encouragement will be given during the test.  Eye contact with the 
subject should be avoided during the test.  
Following the walk, the person administering the test will obtain a rating of dyspnea using the 
Borg Scale.  The person will use the following dialogue:  
“I would like to use the following scale to indicate the maximal shortness of breath you 
had during the walk test (indicate the Borg Scale).  If there was no shortness of breath at 
all you would point to 0; if the shortness  of breath was not very great you would choose 
from 0.5 to 2; if you were somewhat more short of breath you would select 3; and if the 
breathing was getting very difficult, you would choose 4 to 9, depending on just how hard 
it was; 10 represents the great est shortness of breath you have ever experienced in your 
life, and if you feel more short of breath than you have ever been in your life before, 
choose a number greater than 10 that represents how short of breath you feel.  If one of the 
numbers does not exactly represent how short of breath you are, then you can choose a 
fraction between.  For example, if you had shortness of breath somewhere between 4 and 
5, you could choose 4 ½.  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 49 15.2 WHO FUNCTIONAL CLASS  FOR PAH  
Class I :   Patients with pulmonary hypertensio n but without resulting limitation of physical 
activity.  Ordinary physical activity does not cause undue dyspnea or fatigue, chest 
pain, or near syncope.  
Class II :   Patients with pulmonary hypertension resulting in slight limitation of physical 
activity.  These subjects are comfortable at rest, but ordinary physical activity 
causes undue dyspnea or fatigue, chest pain or near syncope.  
Class III :   Patients with pulmonary hypertension resulting in marked limitation of physical 
activity.  They are comfortable at rest.  Ordinary activity causes undue dyspnea or 
fatigue, chest pain, or near syncope.  
Class IV :  Patients with pulmonary hypertension with inability to carry out any physical 
activity without symptoms.  These subjects manifest sign s of right heart failure. 
Dyspnea and/or fatigue may be present even at rest.  Discomfort is increased by 
any physical activity.  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 50 15.3 CLINICAL LABORATORY  PARAMETERS  
Blood Chemistries  Hematology  Other  
Sodium  Red Blood Cell Count  NT-proBNP (plasma) * 
Potassium  Hemoglobin  Urine dipstick analysis* * 
Chloride  Hematocrit  Urine pregnancy test** * 
Bicarbonate/ CO 2 Platelet Count   
Albumin  White Blood Cell Count (no differential)   
Blood Urea Nitrogen /Urea    
Total Bilirubin    
Indirect Bilirubin    
Direct Bilirubin    
Alkaline Phosphatase    
Alanine Aminotransferase (ALT)    
Aspartate Aminotransferase (AST)    
Gamma -glutamyl transferase 
(GGT)    
Creatinine    
 
Visit Test Schedule  
Visit  Labs Collected  
Baseline /Study Entry **** Chemistries, Hematology, NT -proBNP, urine dipstick, urine 
pregnancy *** 
Week  6 Visit  Urine pregnanc y*** 
Week 12  Visit  Chemistries,  Hematology , urine pregnancy *** 
Follow -up Visits **** * Chemistries , Hematology, NT -proBNP *, urine pregnancy *** 
Study Termination  Visit  Chemistries, Hematology, urine dipstick, urine pregnancy *** 
* NT-proBNP collected at Baseline /Study Entry and Follow -up Visit (Week 48) only  
** pH, specific gravity, presence of protein or blood  
*** For women of childbearing potential (WOCBP)  
**** Baseline /Study E ntry clinical laboratory assessments for this study are those collected at the last visit (Study 
Termination) from study TDE -PH-310 and prior to initiation of open -label  UT-15C. 
**** * During Follow -up Visits, clinical laboratory samples should be collected at the first Follow -up Visit and every 
other Follow -up Visit thereafter . 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 51 15.4 GUIDELINES AND DEFINITIONS  FOR RECORDING ADVER SE EVENTS  
The Principal Investigator or a designated member of his /her staff will probe each subject for 
any AEs that may have occurred.  The Investig ator should always ask the same question when 
conducting the verbal probe in order to ensure uniformity between subjects.  The Investigator 
should ask:  
 “How are you doing (feeling)?”  
Based on the subject’s response to this question, the Investigator shoul d ask additional 
questions relevant to the specific complaint such as:  
 “How severe is /was the symptom?”  
 “How often did the symptom occur?”  
 “How long did the symptom last?”  
Using provided definitions, the Investigator will then:  
(1) rate the intensity an d seriousness of the AE, (2) estimate the causality of the AE to study 
drug, and (3) note actions taken to counteract the AE.  
Definitions of Intensity, Seriousness, Causality, Action Taken , and Outcome  
INTENSITY  
An assessment of the relative intensity (severity) of an AE is based on the Investigator’s 
clinical judgment.  The maximum intensity encountered during the evaluation period should 
be checked.  The assessment of intensity should be independent of the asses sment of the 
seriousness of the AE.  
SERIOUSNESS  
A SAE is one that represents an actual or potential significant hazard.  This includes, but is 
not limited to, an event that is fatal, life -threatening, permanently or severely disabling, 
requires or prolong s inpatient hospitalization, is a congenital abnormality (offspring of 
subject) or is medically significant (important medical events that may not result in death, be 
life-threatening, or require hospitalization may be considered a SAE when, based upon 
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 52 appropriate medical judgment, they may jeopardize the subject and may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition).  
CAUSALITY  
An estimate of causality between a specified AE and the study drug is made by t he 
Investigator.  Definitions of the categories follow:  
 NOT RELATED  - there is not a temporal relationship to study drug administration 
(too early, or late, or study drug not taken), or there is a reasonable causal relationship 
between another drug, or con current disease and the SAE  
 POSSIBLE  - there is a reasonable causal relationship between the study drug and the 
SAE.  Dechallenge information is lacking or unclear  
 PROBABLE  - there is a reasonable causal relationship between the study drug and the 
SAE.  The event responds to dechallenge.  Rechallenge is not required  
ACTION TAKEN  
 TEST AGENT DOSE MODIFICATION*  
 Dose Increased - the dose or regimen of the test agent was increased  
 Dose Not Changed - the dose or regimen of the test agent was not changed  
 Dose Re duced - the dose or regimen of the test agent was decreased  
 Drug Interrupted - administration of the test agent was stopped temporarily  
 Drug Withdrawn - administration of the test agent was stopped permanently and not 
restarted  
 Unknown - changes to the adm inistration of the test agent cannot be determined  
*NOTE:  Only the last test agent action should be recorded in the eCRF.  
OUTCOME  
 Fatal – The study subject died  
 Not Recovered / Not Resolved – The AE was ongoing  
 Recovered / Resolved – The AE resolved  
 Recov ered / Resolved with Sequelae – The AE is considered resolved however there is 
a residual sequelae   
 Recovering / Resolving – The AE is improving but is not yet completely recovered / 
resolved  
 Unknown – The outcome of the AE cannot be determined  
United Therapeutics Corporation  TDE -PH-311 Amendment 7  
 Oral Treprostinil  
Version date: 13 July 2018  Confidential  Page 53 15.5 EXPECTED EV ENTS ATTRIBUTABLE TO  THE PROGRESSION OF 
PULMONARY ARTERIAL  HYPERTENSION (SYSTE M ORGAN CLASS 
AND PREFERRED TERM, VER. 16.0)  
Abdominal pain (Gastrointestinal disorders; 
ABDOMINAL PAIN)  Hemoptysis (Respiratory, thoracic & mediastinal 
disorders; HAEMOPTYSIS)  
Anorexia (Metabolism and nutrition 
disorders; ANOREXIA)  Hypoxia (Respiratory, thoracic & mediastinal 
disorders; HYPOXIA)  
Ascites (Gastrointestinal disorders; 
ASCITES)  Loss of consciousness  
(Nervous system disorders; LOSS OF 
CONSCIOUSNESS)  
Cardiac arrhyt hmia (Cardiac disorders; 
ARRHYTHMIA)  Nausea (Gastrointestinal disorders; NAUSEA)  
Cardiac arrest (Cardiac disorders; CARDIAC 
ARREST)  Edema (General disorders and administration site 
conditions; OEDEMA)  
Heart failure (including exacerbation of) 
(Cardiac disorders; CARDIAC FAILURE)  Orthopnea (Cardiac disorders; ORTHOPNOEA)  
Chest pain (General disorders and 
administration site conditions; CHEST PAIN)  Pallor (Vascular disorders; PALLOR)  
Cardiovascular collapse (Vascular disorders; 
CIRCULATORY COLLAPSE)  Palpitations (Cardiac disorders; PALPITATIONS)  
Cor pulmonale (Cardiac disorders;  
COR PULMONALE)  Cool extremities  
(General disorders and administration site 
conditions; PERIPHERAL COLDNESS)  
Cough (Respiratory, thoracic & mediastinal 
disorders; COUGH)  Pulmonary arterial hypertension, exacerbation of 
(Vascular disorders; PULMONARY ARTERIAL 
HYPERTENSION)  
Cyanosis (Cardiac disorders; CYANOSIS)  Sudden death (Cardiac disorders; SUDDEN 
DEATH)  
Dizziness (Cardiac disorders; DIZZINESS)  Syncope (Cardiac disorders ; SYNCOPE)  
Dyspnea at rest (Respiratory, thoracic & 
mediastinal disorders; DYSPNOEA)  Vasovagal reaction (Nervous system disorders; 
SYNCOPE VASOVAGAL)  
Dyspnea on exertion  
(Respiratory, thoracic & mediastinal 
disorders; DYSPNOEA EXERTIONAL)  Tachycardia (C ardiac disorders; 
TACHYCARDIA)  
Paroxysmal nocturnal dyspnea  
(Cardiac disorders; DYSPNOEA 
PAROXYSMAL NOCTURNAL)  Vomiting (Gastrointestinal disorders; VOMITING)  
Exercise intolerance (General disorders and 
administration site conditions; EXERCISE 
TOLERANCE  DECREASED)  Weight loss (Investigations; WEIGHT 
DECREASED)  
Fatigue (General disorders and administration 
site conditions; FATIGUE)  Weight gain (Investigations; WEIGHT 
INCREASED)  
 